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extracellular matrix components in women with pelvic floor dysfunction 
 
by Annette Thiem 
 
Stress incontinence (SI) is more common in white women (61%) than in black 
African women (27%). Previous studies have demonstrated that collagen XVII is 
increased and the collagen I:III ratio is decreased in continent black women 
compared to white suggesting better adhesiveness and elasticity in the tissue of 
black women. We decided to examine this concept further and analyse the 
elastin content in paraurethral vaginal tissue of black and white women with or 
without stress incontinence. A further study was set up to examine if topical 
oestrogen could increase elastin and change associated components of white 
women with pelvic organ prolapse (POP). Oestrogen treatment has been shown 
to increase pro-mmp2 and new collagen formation in SI women, therefore it 
seemed possible that such treatment could affect the collagen and elastin 
components of POP favourably. The clinical symptoms of POP and surgical 
outcome may also be improved. 
 
  The first study examined the elastin content by histochemistry in paraurethral 
vaginal tissue while the second study assessed how locally applied oestrogen 
(Vagifem) given over three months influenced the mRNA expression of MMP2, 
elastin and collagen XVII and also elastin, collagen I and collagen III protein 
content of vaginal skin from women with POP. 
 
    In the racial comparison study black controls showed a highly significant 
increase in elastin content compared with white controls (p<0.01). For SI to occur 
in black women a severe insult that reduces elastin production appears to be 
necessary as black women with SI showed significantly lower elastin content 
compared with black controls (p<0.05).  
 
  After application of topical oestrogen to white women with POP it was shown 
that mRNA for MMP2 is up-regulated (p<0.01) while that for ER alpha receptor is 
not (p=NS). The message for collagen XVII was down-regulated (p<0.01) while 
collagen I and III protein were increased significantly (p<0.001 in both cases). 
The mRNA for elastin was significantly increased (p<0.05) after treatment but the 
increase in elastin protein staining did not quite reach significance. 
 
    In conclusion, black women have higher elastin content in vaginal tissue 
compared to white and this may contribute to the lower incidence of SI in black 
women. Topical oestrogen over a short period has remodelling effects on key 
factors of the extracellular matrix of vaginal tissue. Although significant rises in 
elastin mRNA were shown but not protein, this treatment over longer term 
application could enhance some of the changes seen. This research provides 
evidence that black women have beneficial characteristics of vaginal skin that 
could resist SI and POP. Oestrogen treatment with refinements for white women 
could mimic black characteristics and alleviate POP symptoms. 3 
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1.1 Background 
 
This thesis examines the presence of elastin in periurethral vaginal tissue of 
women from different races and assesses any diverse changes occurring when 
associated with stress incontinence. It also investigates the influence of vaginal 
oestrogen on elastin and associated extracellular matrix components in vaginal 
tissue from women with pelvic organ prolapse.  
 
The pathophysiology of stress incontinence and pelvic organ prolapse and 
comparison to the normal anatomy are also presented in this Introduction. 
 
 
1.2 Normal  Anatomy 
 
The support apparatus in the female pelvis is derived from different tissues, 
anatomical layout and their cooperation. The pelvic diaphragm is the key 
structure to prevent pelvic organ prolapse. In combination with the uterine, 
ovarian and vesical ligaments it acts as a support unit for the pelvis and its 
contents. The pelvic diaphragm consists of interacting and connected muscles 
fanning out and so building a muscle plate. 
 16 
 
The main muscle is the levator ani muscle. This muscle has been divided into 
three different parts:  
    1)  pubococcygeal  muscle, 
    2)  ileococcygeus  muscle, 
    3)  puborectalis  muscle 
 
Further important muscles are 
    4)  ischiococcygeus  muscle 
    5)  Obturator  internus  muscle 
 
The pubococcygeus and ileococcygeus form the main part of the levator though 
the iliococcygeus, the most posterior part of the levator ani, is often poorly 
developed. They run backward from the pubic bone toward the coccyx and may 
be damaged during delivery. Some fibres are inserted into the urethra and vagina 
so that the muscle acts as a plate which is lying over the urogenital hiatus. Anal 
ultrasound studies have shown that the urogenital hiatus widens when the levator 
ani muscles relax and the supporting ligaments are left to hold the uterus and 
other viscera alone.
1 
 
The right and left puborectales unite behind the anorectal junction to form a 
muscular sling. Some regard them as a part of the sphincter ani externus. The 
levator ani muscles as well as the external anal sphincter muscle are innervated 
by the pudendal nerve, deriving from S2-4. 
 17 
 
The muscles and vagina interact with the different ligaments. DeLancey 
describes the anatomy of vaginal vault prolapse in terms of 3 levels of support  
  
  Level I involves the support of the upper vagina and cervix or the vaginal 
  cuff (in a woman who  has undergone total hysterectomy) by the cardinal-
  uterosacral ligament complex. 
  Level II denotes the lateral support of the mid vagina to the arcus 
  tendineus fascia pelvis (white line). 
  Level III is represented by the fusion of tissue along the base of the 
  urethra and the distal  rectovaginal septum to the perineal body.
2 
 
 
Figure 1.1 Three levels of support (from DeLancey) 
 
The endopelvic fascia is a tissue compound overlying the entire pelvic floor and 
connecting the different muscle parts and forming the pelvic ligaments thus 
granting extra support. The fascia is mainly composed of connective tissue and 
smooth muscle. 
Anteriorly, it forms the pubourethral ligaments arising either side of the urethra 
and supporting its proximal aspect. These ligaments extend anteriorly and end as 18 
 
the suspensory ligaments of the clitoris. Further the pelvic fascia extends 
posteriorly and so connects the symphysis pubis with the ischial spine. This is the 
“arcus tendineus fascia pelvis” also commonly referred to as the “white line”. 
 
The uterosacral and cardinal ligaments are important ligaments that form from 
fascial thickening at the posterior and lateral aspect of the uterus and the 
parametrium and paracolpium are fascial continuations around the uterus and 
vagina respectively. 
 
 
1.3 Vaginal  Wall 
 
1.3.1  Anatomy and Histology of the Vagina and the Vaginal Wall 
 
The vagina is not a support structure for the pelvic floor as such but its 
anatomical direction plays a role in preventing POP. It stretches at a length of 
around 7-8cm from the introitus vaginae posteriorly tilted upwards to the uterine 
cervix. It is supported and kept in its anatomical position by the paracolpium, the 
urethrovesical ligaments and the pelvic fascia between bladder anteriorly and 
rectum posteriorly. 
 
The vagina is of dual origin during embryological development. The caudal part 
derives from the sinuvaginal bulb and the cranial part from the uterine canal 
(paramesonephric ducts) thus connecting the inner genital organs with the 
exterior part.
89 The lower part, is mainly but not totally, closed by a fibrous tissue 
ring, the hymen. The fibrous-muscular vaginal wall is only 2-4 millimetres thin and 19 
 
has four layers. The mucosa is combining the epithelium and lamina propria. It 
consists of only 30 cell layers and is non-keratinized squamous epithelium. 
 
The layers of the vaginal wall: 
 
o Mucosa: stratified nonkeratinized squamous epithelial tissue with: 
superficial stratum  
intermediate stratum 
parabasal stratum 
basal stratum 
lamina propria 
o Submucosa: vascularised connective tissue 
o Muscularis: smooth muscle, inner circular and  outer, thicker   longitudinal  
  muscle 
o Adventitia 
 
  Lamina propria 
Figure 1.2 Vaginal wall histological profile 20 
 
Pelvic Floor Dysfunction 
 
The term pelvic floor dysfunction (PFD) describes a variety of changes and 
disturbances in the normal anatomy and physiology of the pelvic floor 
components. PFD has varying end results but often with considerable and grave 
impacts on the quality of life and normal day to day functionality of patients. 
Stress incontinence and pelvic organ prolapse are types of PFD.  
 
 
1.3.2  Pelvic Organ Prolapse 
 
Pelvic organ prolapse (POP) or genitourinary prolapse is defined as the 
protrusion of a pelvic organ beyond its normal anatomical confines.  This 
condition affects 15 % of the overall female population and almost 50% of parous 
women in later life of which 20% are symptomatic. 
3 Currently surgery is the first 
line treatment for symptomatic prolapse. 20% of patients on the waiting lists for 
major gynaecological surgery are waiting for a prolapse repair. In view of distress 
and surgical risks, research that improves the knowledge about this condition 
could reduce the prevalence and improve treatment. 
 
 
1.3.3  Classification and grading of Pelvic Organ Prolapse 
 
The classification of pelvic organ prolapse is dependent on the protruding organ 
into the vagina. The grading describes the degree of descent into or beyond the 
vagina. 21 
 
Classification: 
 
Apical/Middle:  
Uterus              uterine prolapse/procidentia 
Vaginal Vault           vault prolapse  
Omentum and small bowel        enterocele 
 
Anterior:  
Bladder           cystocele 
Urethra           urethrocele 
 
Posterior: 
Rectum        rectocele 
     
Figure 1.3 Anatomical representations of different types of pelvic organ prolapse 
 
Grading: 
 
grade 1  protrusion of a pelvic organ into the vagina but the lowest 
part has not reached the hymenal ring. 
grade 2    protrusion to the hymenal ring 
grade 3  protrusion beyond the hymenal ring and in case of uterine 
prolapse: procidentia 
 
Another grading system that attempts to establish a more specific description of 
prolapse is the POP-Q described in the Table below. 22 
 
 
 
Figure 1.4 POP-Q, Pelvic Organ Prolapse Assessment Tool 
 
Aa   point in the midline of the anterior vaginal wall 3cm proximal to the  
    urethral external meatus 
Ba  most distal position of the anterior vaginal wall from the vaginal  
    vault to Aa 
C   most distal edge of the cervix or vault 
D   location of the posterior fornix 
Ap  point in the midline of the posterior vaginal wall 3 cm proximal to  
   the  hymen 
Bp  most distal point of posterior vaginal wall from vault or posterior  
    fornix to Ap 
GH  genital hiatus measured from the middle of the external urethral 
    meatus to the posterior midline of the hymen 
PB  perineal body measured from the posterior margin of the genital 
     hiatus to the middle of the anus 
Tvl  total vaginal length  
 23 
 
The examination is usually performed whilst the patient is performing the 
Valsalva manoeuvre. Points Aa, Ab, Pa, Pb are assessed using a Sim’s 
speculum. The anterior or posterior vaginal wall is hereby retracted to 
assess the opposite side for prolapse. A Cuscoe’s speculum and a device 
marked in 1cm steps are used to measure point C and D. 
 
The staging is similar to that of Walker and Baden: 
0   no descent during straining 
I    leading surface of the prolapse does not 
    descent below 1cm above the hymenal ring 
II   Leading edge of the prolapse extends from  
    1cm above to 1cm below the hymenal ring 
III  from 1cm of the hymenal ring but without 
    complete vaginal eversion 
IV  complete eversion of vagina 
 
The purpose of the ICS POP Quantitative Staging or Scoring System (ICS 
POP-Q) is a standardised form of measuring pelvic organ prolapse. It was 
found to be reliable and reproducible in evaluating studies.
4 
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Grading systems history: 
 
 
 
Vagina 
Uterus 
2
nd 
degree 
3
rd 
degree 
Grade III 
Grade I  1
st 
degree 
Grade II 
1
st 
degree
Grade IV 
2
nd 
degree
3
rd 
degree
Introitus 
Hymen 
Stage I 
Stage III 
Stage II 
Stage IV 
Porges 
1963 
Baden 
1972 
Beecham 
1980
POP 
1996 
-1cm 
+1c
complete 
eversion 
Figure 1.5 History of commonly used pelvic organ grading systems. POP is the currently 
used system and the system used in this study (schematic, original by Steven Swift and 
John Theofrastous) 25 
 
1.3.4  Symptoms of Pelvic Organ Prolapse 
 
Pelvic organ prolapse can be irritating for women and diminish their quality of life 
significantly. Symptoms can vary from a dragging feeling in the vagina which is 
often described as the feeling like “sitting on an egg” or “feeling a lump between 
the legs”, to significant pain abdominally or in the back. Ulcerations and infections 
are common complications and dyspareunia or other problems during intercourse 
such as urinary or faecal which not as uncommon as previously thought can lead 
severe impairment in functioning for patient and partner. In 60% percent of the 
cases either stress incontinence symptoms or urgency with urge incontinence 
occurs or both are present as mixed incontinence.
5  
 
 
1.3.5  Management of Pelvic Organ Prolapse 
 
1.3.5.1 Examination 
 
An initial detailed history should be taken and the patient assessed thoroughly 
including symptoms, their severity and length of time that the problem has been 
present. This is followed by a gentle but thorough abdominal and pelvic 
examination. Abdominal palpation is crucial to exclude any underlying pathology 
that is not related to prolapse such as pelvic masses which could be of ovarian 
origin or uterine fibroids. Vaginal examination is usually performed bimanually in 
dorsal lithotomy position but an upright position with one of the patient’s legs 
standing on a chair can give a better and more obvious assessment of the 
prolapse. Additional speculum examination, either with a Cuscoe or Sims 
speculum is required to assess not only the prolapse but also health of cervix and 26 
 
vaginal walls. Examination with a Sims speculum should be performed in the left 
lateral position. A rectal examination should be performed to exclude or assess a 
rectocele, enterocele and to identify possible anal sphincter dysfunction. 
 
The pelvic floor muscles need to be examined to establish strength and function. 
For this the patient lies on her back with the legs in parallel position and tries to 
apply pressure to the examiners digits. The thickness of the pelvic floor muscle 
diaphragm should be felt and the length of pelvic floor contraction established. 
 
Patients with additional urinary incontinence might need urodynamic studies prior 
to surgery and patients with rectal or faecal problems may require a referral to 
colorectal specialists for anorectal manometry, transanal ultrasound scanning or 
defecography to exclude sphincter defects or motility problems. 
 
There are different approaches available to improve prolapse symptoms or 
quality of life issues. The patient can often be offered a choice between 
conservative and surgical options. 
 
 
1.3.5.2 Conservative  Options 
 
The least invasive treatment is the most common and most important option. 
Obesity, smoking or chronic cough should be treated initially. Conservative 
options include pelvic floor exercises. These are mentioned as a possibility but 
not recommended if the prolapse is larger than grade 1 or only if the patient is 
either not suitable for or interested in other possibilities.
6 
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Other conservative options are vaginal pessaries in various shapes and sizes. 
The one most commonly used in the UK is the Hodge-ring-pessary. Made of 
flexible latex, it is available in sizes between 30 and 100mm in diameter and 
gives support to the anterior and posterior vaginal wall as well as any apical 
descent. Other pessaries such as are the Simpson shelf pessary available in size 
8 to 14, or the Arabin cube pessary. (Latter is not routinely being used in the UK.) 
A large variety of pessaries with or without extra support of the urethra are used 
in other countries such as USA, Australia or Canada
7. 
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Figure 1.6 Hodge standard ring pessary, here size 77mm 
 
 
 
     
Figure 1.7 Simpson shelf pessary, here size 13 
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1.3.5.3 Surgical  Options 
Since the beginning of the 20
th century various surgical techniques have been 
described for pelvic organ prolapse. White described that for treatment of a 
cystocele the surgeon should reapproximate the lateral vaginal fornices to the 
arcus tendineus. Kelly strongly supported the plication technique and midline 
plication for cystocele repair. Richardson
8 published his classification of fascial 
defects in 1976 in which he illustrated lateral, transverse (superior), and midline 
defects in the pubocervical fascia. Repair was directed at the site of the specific 
defect. The definition of paravaginal defects was characterised as a detachment 
of the endopelvic fascia from the arcus tendineus fascia pelvis. These changes 
were found in 67% of patients with anterior vaginal prolapse. Paravaginal repair 
techniques were developed to repair this type of prolapse. These can be 
performed via the vaginal or the abdominal approach. Benson
9 for example 
defends the abdominal approach after he discovered that the pudendal and 
perineal nerve terminal motor latencies after vaginal dissection were delayed. 
 
 
Anterior Compartment  
 
Some form of the anterior colporraphy is still used as the gold standard to repair 
a cystocele or urethrocele. This technique can be used in combination with a 
sling plasty such as the tension free vaginal tape insertion when urodynamically 
proven stress incontinence co-exists. In later years the insertion of either organic 
or synthetic mesh (medium pored mesh, mainly polypropylene) which is attached 
to the pelvic fascia on either side of the prolapse to secure extra support to the 
tissue, has been used to attempt to reduce the risk of recurrence. However, they 
are associated with an increase in surgical complications, like mesh erosion, 30 
 
fistula and dyspareunia. Raz et al 
10 developed a new technique to repair large 
anterior vaginal wall defects such as grade IV cystourethrocele. An anterior 
colporrhaphy is performed to correct the central defect of the cystocele and in 
addition a repair of the paravaginal herniation of the bladder and bladder neck is 
performed by a needle suspension.  
 
Paravaginal repair: 
A paravaginal repair for the correction of a cystocele attaches the lateral vagina 
at the level of the arcus tendineus. A longitudinal incision of the anterior wall of 
the vagina is made and dissected upwards and laterally along the inferior pubic 
ramus, medially to the pubis and laterally to the ischial spine. Stitches are 
positioned in the white line, into the pubocervical fascia and into the vaginal 
epithelium. Further stitches are positioned posteriorly and towards the ischial 
spine. They are attached to the vaginal apex. The vaginal muscularis can be 
plicated in the midline. Redundant epithelium is excised before closure with 
absorbable sutures. 
 
Abdominal and laparoscopic paravaginal repair: 
Scotti et al recruited 40 women with lateral vaginal wall detachment. Paravaginal 
fixation to the ischial periosteum and obturator membrane was performed. The 
suture was passed through the arcus tendineus and obturator internus muscle, 
piercing the periosteum and obturator membrane after careful palpation of the 
ischial spine and sciatic foramen to ensure safe and anatomically correct suture 
placement. He found that the ischial periosteum and obturator membrane are 
consistently strong reattachment sites so that repair of paravaginal defects with 
these tissues is effective and safe.
11 31 
 
Posterior Compartment 
 
Two different routes to repair posterior vaginal wall defect are used. The vaginal 
route is preferred and performed by gynaecologists meanwhile the transanal 
route is referred by colorectal surgeons. Here are examples for gynaecological 
approaches. 
 
Posterior colporrhaphy: 
Posterior colporrhaphy is performed through a midline or diamond shaped 
incision in the posterior vaginal wall. Interrupted sutures are set in the 
rectovaginal fascia and the margins of the levator ani muscles are plicated with a 
second layer of interrupted stitches. The vaginal mucosa is trimmed and closed 
with delayed absorbable sutures.  
 
Transverse repair: 
Marek et al modified a transanal technique in 1969
12. One finger is inserted into 
the rectum and the margins of the rectocele demarcated. Allis clamps are placed 
laterally and traction applied. The mucosa is removed from side to side, 
superiorly and inferiorly until the rectocele is exposed. The wound is closed with a 
continuous lockstitch suture through the perirectal fascia. This stitch can include 
the superficial muscularis layer of the rectum. 
 
Transrectal repair: 
The incision in this technique is made 1 cm above the dentate line. Dissection is 
performed anteriorly and laterally. The rectal muscle and the rectovaginal septum 
in this area is plicated with interrupted sutures. Closure of the mucosal defect 
follows with a second layer. 32 
 
Laparoscopic rectocele repair: 
With the availability of minimally invasive instruments, laparoscopic techniques to 
effect enterocele and rectocele repair can be used. Cadeddu et al examined 
women that underwent a transperitoneal laparoscopic enterocele repair prior to a 
transvaginal rectocele or cystocele repair or laparoscopic colposuspension. The 
enterocele was repaired utilizing a modified Moschowitz technique. The cul-de-
sac was obliterated by approximating the posterior vaginal fascia to the anterior 
wall of the rectum with a running suture. The group had no morbidity, an average 
length of stay of 3.3 days and all patients were asymptomatic with no enterocele 
recurrence identified during a mean follow-up of 10.5 (range 7-15) months.
13 
 
Fascial repair: 
Denonvilliers, Uhlenhuth
14 and others demonstrated the existence of a 
rectovaginal septum. Richardson attributed defects in this fascia as the cause of 
rectoceles. He was one of the first gynaecologists to support the reapproximation 
of these fascial breaches to restore anatomy integrity.
15 A diamond shaped 
incision at the introitus is made and the vaginal mucosa reflected laterally. Whilst 
one finger is placed in the rectum the edges of the connective tissue are 
approximated. The edges are plicated with interrupted sutures and redundant 
skin is excised and edges sutured. 
 
The outcome of all techniques is dependent on the pre-existing tissue. The 
degree of tissue damage, already present through the present prolapse, 
influences the possibilities to restore normal anatomy. The lower the tissue 
quality is, the higher is the recurrence rate after surgical repair. Mesh can be 
used if tissue quality is poor. It can add extra support and various types of 
meshes have been introduced and used for the anterior and the posterior vaginal 
wall. There are synthetic and organic options. A disadvantage with both groups is 33 
 
increased risk of infection, erosion and dyspareunia. Therefore meshes are used 
for recurrent cases or elderly patients who are preferably not sexually active.  
 
 
Uterine Prolapse  
 
The method of choice for a uterine prolapse is the vaginal hysterectomy if the 
patient has completed her family. If the patient wishes to maintain her uterus a 
sacrohysteropexy can be performed where the posterior uterovaginal junction is 
attached to the anterior longitudinal ligament of the first or second sacral vertebra 
with a polypropylene mesh. A similar procedure is the sacrocolpopexy which is 
performed for a vaginal vault prolapse after hysterectomy. Instead of the cervix 
the vaginal vault is connected to the sacral periosteum with a polypropylene 
mesh. 
 
Other methods are the sacrospinous or ileococcygeal fixation and a newer but 
more doubtful option is the infracoccygeal sacropexy, more commonly known as 
posterior intravaginal sling plasty (IVS). This operation involves a piece of 
surgical mesh attached to the top of the vagina. The mesh extends through the 
pelvic sidewalls and emerges from the buttock on each side. It acts to strengthen 
and replace the weakened uterosacral ligaments which suspend the top of the 
vagina in its normal anatomic position. Many other mesh kits have been used and 
are currently awaiting appropriate evaluation. 
 
Prevention of prolapse is a more important than developing surgical technique as 
the outcome can vary significantly. It is vital, if possible, to improve the quality of 
pelvic floor tissue in susceptible women prior to development of pelvic organ.  
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1.3.6 Stress  Incontinence 
 
Stress incontinence (SI) is defined as involuntary leakage when strain is applied 
to the pelvic floor and urethral sphincter muscle through an increase in intra-
abdominal pressure, e.g. whilst coughing, sneezing or during physical exercise. 
The International Continence Society (ICS) defines stress incontinence as an 
involuntary loss of urine which is objectively demonstrable and a social and 
hygienic problem". Urodynamic stress incontinence is a cystometric diagnosis 
defined as “the involuntary loss of urine that occurs when, in the absence of 
detrusor contraction, the intravesical pressure exceeds the maximum urethral 
pressure. 
16 Accurate and detailed history taking, thorough examination and 
urodynamic studies confirm the diagnosis. During urodynamic assessment 
leakage is confirmed with absence of detrusor muscle overactivity. 
 
Stress incontinence is caused by either urethral hypermobility occurring through 
deficiency of support by the surrounding tissues or genuine weakness of the 
urethral sphincter muscle. The currently still used classification of stress 
incontinence was developed by Green in 1962: 
  Type I    absence of the posterior urethrovesical angle without  
   urethra  hypermobility 
  Type II   absence of the posterior urethrovesical angle with    
   urethra  hypermobility 
  Type III  fixed urethra with low urethral closure pressure (<20cm  
   H 2O) 
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1.3.6.1  Maintaining Continence  
 
Urinary continence is sustained by various factors. It depends not only on urethral 
sphincter tone, providing urethral closure pressure, but of further importance is 
the position of the bladder neck. It has to be positioned intraabdominally so that 
increases in intra-abdominal pressure are transmitted equally to bladder and 
bladder neck. Through the simultaneous rise in intravesical and urethral 
pressure, the urethra is compressed and leakage prevented. Posterior angulation 
also helps to prevent leakage when a rise in intraabdominal pressure occurs. 
Through connection of the anterior vaginal wall, levator ani and arcus tendineous, 
the endopelvic fascia and the paravaginal tissue, all acting as a hammock 
underneath the urethra, increases in intra-abdominal pressure can be 
counteracted. 
 
Further urethral closure is supported by pubococcygeus muscle contractions and 
the extrinsic urethral sphincter fibres. Petros and Ulmsten describe the 
pubococcygeus muscle as the first level of closure mechanism to achieve 
continence. The contraction of the anterior pubococcygeus muscle brings the 
vaginal hammock forward and closes the urethra. The second level, at the 
bladder neck, is made of uterosacral and pubourethral ligaments which support 
and fix the proximal urethra. With pubococcygeus muscle contractions an 
elongation backwards and downwards of the bladder neck is caused and the 
urethra is fixed. Muscular fibres at the urethrovesical junction shape the urethral 
internal sphincter. These are mainly circular fibres and are accountable for 
continence. These fibres are surrounded by striated muscle fibres, building the 
external urethral sphincter. With attachment of some fibres to the pubic bone, 
compressor urethrae, the urethrovaginal sphincter is composed. Smooth circular 
and longitudinal muscle fibres constrict and shorten urethral lumen and effectuate 36 
 
the shortening and funneling of the urethra during micturition. These fibres are 
slow-twitch fibres and maintain a constant tone keeping the resting urethral 
closure pressure. The pelvic floor muscles (puborectalis and pubococyggeus) are 
the third mechanism of urethral closure. If trained they can be involved in urethral 
closure
17. Thus, pelvic floor exercises are an effective tool to re-learn 
incontinence.
18  
 
Connective tissue is one of the important components of the pelvic floor in 
maintaining continence and structural support, together with muscular support. 
Pelvic fascia would be the obvious tissue to study as skeletal muscle is more 
sensitive than tendon to mechanical stimulus, seen by a more marked increase in 
the expression of TGF-beta 1, collagen I and III in response to muscle contraction 
in rat skeletal muscle compared to tendon 
19. Physical activity would not alter 
pelvic fascia as significantly. As vaginal skin can be taken as a representative of 
pelvic fascia and is easier to access, we decided to sample and study full 
thickness periurethral vaginal skin for both studies. 
 
 
1.3.7   Treatment of stress incontinence 
1.3.7.1 Conservative  management 
 
Conservative management should be the first line of treatment. Pelvic floor 
exercises and bladder retraining are known to be more effective if they are 
associated with changes in life style. Life style changes include weight loss, 
caffeine reduction, smoking cessation, balanced fluid intake, reducing physical 
strain on the pelvic floor and relief of constipation. 
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Women with high BMI show a higher prevalence of SI. Dwyer examined 368 
women and demonstrated that stress incontinence was more common in obese 
women
20 . Bump et al assessed the weight loss in moderately obese women and 
demonstrated an association between weight loss and improvement in urinary 
incontinence symptoms
21. Some studies suggest that smoking increases the risk 
of developing urinary incontinence. The more common chronic cough in smokers 
and the influence of smoking on connective tissue are factors that increase the 
risk of SI.  
 
Pelvic floor muscle training is a very important part to re-establish stress 
incontinence. Additional electrical stimulation, biofeedback and usage of devices 
like vaginal cones can give extra support. Recent studies have shown the 
superiority of pelvic muscle training versus no treatment for urinary stress 
incontinence with a success rate of 68 to 74%
22. Supportive devices such as 
vaginal cones or electrical stimulation were found to be very helpful in 
combination with PFE but not as treatment alone.  
 
 
1.3.7.2 Medical  treatment 
 
A recent new serotonin (5-HT) and noradrenalin (NA) reuptake inhibitor, 
Duloxetine has been approved for the treatment of stress urinary incontinence. 
Duloxetine acts on the sacral spinal cord in animal studies where it increases the 
concentration of 5-HT and NA. Thus it increases the activity of the external 
urethral sphincter and prevents involuntary urinary leakage. There is no influence 
on micturition as the external sphincter muscle action is controlled by glutamine 
and not by 5-H and NA. Duloxetine in combination with pelvic floor exercises are 
more effective than no treatment. 38 
 
1.3.7.3 Surgical  treatment 
 
Surgical options should be the next line of treatment. Stress incontinence should 
be proven by urodynamic testing, assessment of symptoms and the patient’s 
health should be considered. The most appropriate surgical technique can then 
be chosen and applied. Below are some options summarized. 
 
Bulking agents: 
Bulking substances are injected into the urethral submucosa at the level of the 
bladder neck. They narrow the urethral lumen and thus prevent SI. The injections 
can be performed paraurethrally or transurethrally. The transurethral use allows a 
direct vision of location of the needle and the bulk effect. This technique is mainly 
used for patients with intrinsic sphincter deficiency and stable detrusor muscle 
with a non-mobile urethra. The first substance used as a bulking agent was 
polytetrafluoroethylene. Problems with this substance are migration into the 
surrounding tissues and granuloma formation. Another option is glutaraldehyde 
cross-linked bovine collagen. It degrades slowly in the tissue but studies have 
shown a success rate of 64 to 95%
23. Other substances used are macroplastique 
and bioplastique made of silicone polymers. Further materials that are being 
studied are allogenic human collagen and autologous cartilage and synthetic 
agents such as microballoon technology, hyaluronic acid with or without 
microsphere technology 
 
Needle suspension: 
The success rate of this procedure is around 70%. Paraurethral tissue is 
connected to the rectus fascia with stainless steel wires. Long term results at five 
and ten years show a drop in the success rate to 43% 
24. This procedure is rarely 
used now. 39 
 
Sling procedures: 
Sling procedures are aiming to create a hammock like support suburethrally 
counteracting bladder neck descent. Autologous fascia lata, cadaveric fascia lata, 
homologus, porcine dermis and porcine intestinal submucosa have been used in 
addition to synthetic materials such as Mersilene, Vicryl, Silastic, Gore-tex, 
Prolene and Marlex. The synthetic materials are stronger but show a higher 
incidence of erosion and wound healing difficulties. The tension free transvaginal 
tape (TVT), was developed in 1994 by Ulmsten
25 As opposed to previous sling 
procedures, the TVT supports the mid urethra instead of the bladder neck. A 
longitudinal vaginal wall incision is made under the mid-urethra along with two 
suprapubic 0.5cm incisions. The paraurethral spaces are dissected bilaterally. 
The Prolene tape is introduced by using two curved needles on either side of the 
urethra aiming at the skin incisions via the retropubic space. It is important that 
no tension is applied with the sling as subsequent fibrosis of the mesh can 
shorten the structure and induce urinary retention. TVT was found to be superior 
in outcome, recovery and post operatively complications when compared to 
colposuspension. Long term outcome at 5 years is 80%  
26 The transobturator 
tape (TOT) is a successful modification of the TVT. In this technique the tape is 
inserted from the inguinal region through the Obturator foramen into the 
paraurethral space. Studies showed similar outcome at 12 months post-surgery. 
One advantage of the TOT is reduced risk of bladder injury, compared to TVT. 
The main disadvantage is a small risk of permanent thigh pain. 
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1.4  Racial Differences in general and in Pelvic Floor Dysfunction 
 
Previous studies have demonstrated that black African women have a 
significantly lower prevalence of stress incontinence even with similar risk factors 
such as parity or menopause.
27 Studies observing differences in other tissues 
such as bone and skin have shown differences in extracellular matrix protein 
content between black and white people.
28 Pelvic ligaments of black women with 
prolapse showed greater collagen content compared to white peers.
29 Hoyte 
showed that levator ani volume was significantly greater in the African-american 
women compared to white-american women. He also found that the levator-
symphysis gap was smaller in the AA and that there were significant differences 
in bladder neck position, urethral angle, and the pubic arch angle.
30 Black women 
have been shown to have a higher bone and muscle mass and have a lower 
incidence of bone fracture and trauma to the connective tissues
31 
32. Compared 
to Caucasian women, black women not only have a lower incidence of stress 
incontinence but also develop pelvic organ prolapse more rarely but they are 
more prone to detrusor over activity and with it urge incontinence and keloid 
formation in the skin.
33 
Other studies examined anatomical differences in stress incontinent women of 
black and white origin and found that black women possess a significantly greater 
urethral volume and a higher mean Kegel urethral closure pressure when 
measured with MRI.
34 Knobel et al demonstrated that the bladder neck in black 
women is situated more proximally and that the urethral length is greater.
 35 More 
recent studies have showen that stress incontinent black women have higher 
collagen I and III content compared to white women and a significantly higher 
collagen XVII expression in periurethral vaginal skin.
36 
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1.5  Pathophysiology and Risk Factors of PFD 
 
The aetiology of POP is so far not completely established but appears to be 
multifactorial. Different mechanisms have been discussed and are widely 
accepted: 
 
  Familial predisposition  
  Body habitus and obesity 
  Mechanical trauma to pelvic floor muscle, damage to nerve supply and 
  injury to endopelvic fascia, parity 
  Hormonal changes, Menopause 
 Smoking 
 
 
1.5.1  Genetics and Familial Predisposition 
 
Studies examining epidemiological evidence suggest a genetic predisposition to 
prolapse and stress incontinence. This could be a result of various different gene 
abnormalities in expression of connective tissue proteins. Twiss et al summarized 
evidence suggesting a genetic basis for the development of urogenital prolapse 
and stress urinary incontinence. They demonstrated that abnormal expression of 
various structural proteins appears to be one of the possible causes. Families 
with an autosomal dominant pattern of transmission of urogenital prolapse with 
high penetrance have been identified. Further, candidate genes have been 
identified that appear to predispose women to urogenital prolapse and stress 
incontinence.
37 One of these candidate genes was examined by Nikolova et al in 
2006. Their data for example suggest that a polymorphism in the promoter of the 42 
 
laminin gamma1 gene (LAMC1) may increase the susceptibility to early-onset 
pelvic organ prolapse.
38 Miedel et al also demonstrated in a controlled study 
examining more than 800 women, that among other non-obstetric risk factors, the 
known familial history of conditions suggestive of deficient connective tissue such 
as varicose veins, hernias or haemorrhoids and showed an increased prevalence 
for positive history compared with no history. Also, family history of prolapse 
showed increased prevalence when compared with no history. However the link 
to family history could be partly due to information bias.
39  Other studies showed 
that daughters of incontinent mothers (urge incontinence was not significant) had 
a 1.3 fold increased risk of being incontinent. Female siblings had a 1.6 fold 
increased risk of urinary incontinence if their older sisters were incontinent
40. A 
twin study examining the bladder neck mobility in monozygotic and dizygotic 
twins suggested a genetic contribution for up to 59% variance for bladder neck 
decent and thus pelvic floor dysfunction
41. 
 
 
1.5.2  Body Habitus and Obesity 
 
Whitcomb et al found that the prevalence of pelvic floor disorders in obese 
women increased with higher degrees of obesity.
42 These findings, supported by 
various similar studies, would concur with clinical experience. It is known that fat 
cells are target cells for oestrogen. Nilsson et al showed that ER alpha mRNA 
expression levels were lower in obese compared to non-obese women in both 
subcutaneous adipose tissue and in adipocytes. These findings support a role for 
oestrogen signalling via ER alpha, in control of body weight.
43  
 
Excessive weight does also mechanically challenge pelvic floor integrity. In 
combination with changes in the hormonal balance of obese women this would 43 
 
furthermore compromise the strength of connective tissue and muscle. 
Wasserberg et al examined the changes in quality of life and symptoms of pelvic 
floor dysfunctions in morbidly obese women that had undergone surgical weight 
reduction. Significant differences in pelvic floor dysfunction symptoms were 
reported.
44 Kapoor et al also found in their pilot study in 2004 that morbid obesity 
is associated with a significant negative impact on urogenital health.
45 
 
 
1.5.3  Mechanical Trauma through Surgery to Pelvic Floor Muscle, Damage 
to Nerve Supply and Injury to Endopelvic Fascia, Pregnancy and 
Parity 
 
Mechanical trauma, for example during child birth has been shown to contribute 
to the development of POP. However pregnancy alone changes connective 
tissue through increasing laxity and collagen degradation. Rectus fascia from 
pregnant women contains less collagen and has more glycosaminoglycans.
46  
Bladder and urethral mobility increase in pregnancy, as well as elbow 
hyperextension, as early as 6-18 weeks gestation.
47 The cervix of pregnant 
women in the third trimester contains less collagen I than the cervix of women in 
the first trimester.
48 It is possible that these findings imply long term changes but 
so far no further studies are available. 
 
Increased birth weight, forceps delivery and perineal trauma seem to increase the 
risk of pelvic organ dysfunction postpartum while vacuum delivery and the length 
of second stage seem not to increase its incidence. Dietz et al showed in 2006 
that inferior aspects of the levator ani and fascial pelvic organ supports such as 
the rectovaginal septum can be injured during child birth. This is associated with 
pelvic organ prolapse, bowel dysfunction, and urinary incontinence.  Pudendal 44 
 
nerve terminal motor latency is prolonged in women after vaginal delivery and 
seems to be longer in multiparous women compared to primigravidae. Further, 
the review found that older age at the first delivery could be associated with a 
higher possibility of trauma.
49 This again could demonstrate that age related 
changes in the pelvic floor are under the influence of oestrogen and the impact of 
hormonal changes over time. In another study, Dietz et al confirmed the high 
incidence of incontinence after vaginal delivery. They showed that injury of the 
inferomedial aspects of the levator ani from the pelvic sidewall occurred in 
approximately one third of all women delivered vaginally and was associated with 
stress incontinence 3 months after childbirth.
50 
 
Recent studies experimenting with endoanal ultrasound and magnetic resonance 
imaging of the pelvic floor after vaginal delivery showed areas of muscle 
insufficiency and thinning as a direct outcome of child birth. This was shown 
during straining and during pelvic floor activity. 
51 Nevertheless, it provides 
evidence of changes in relation to trauma.  
When parous twins were compared in an identical twin study, it was found that 
performing a caesarean section had a 3 fold reduction in SUI risk relative to the 
siblings that delivered vaginally. 200 women were followed up between 2 to 5 
months postpartum and results demonstrated that those who delivered vaginally, 
especially with forceps causing the most changes, showed higher increased 
pelvic organ mobility at valsalva manoevre than those who had any type of 
caesarean section.
52 Nevertheless other studies suggested that caesarean 
section during active labour and vaginal delivery has similar effect on the 
maternal pelvic support 6 weeks postpartum.
53 Pelvic floor muscle strength is 
found to be reduced after vaginal delivery but it is restored almost back to 
antepartum values in 2 months. 
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MRI images showed that the pelvic floor of women with vaginal prolapse had a 
2.5 times increase in likelihood to have major levator ani muscle loss after vaginal 
birth compared to the controls.
54 Furthermore women who had episiotomies 
during vaginal delivery seem to complain more of dyspareunia after delivery than 
women who delivered vaginally without episiotomy. 
 
 
1.5.4  Hormonal Changes and Menopause 
 
The incidence of POP for women after the menopause is significantly higher 
compared to women before the menopause. Some studies demonstrate that a 
lack of oestrogen is a predisposing factor for pelvic organ dysfunctions and even 
that SERMs (Selective Estrogen Receptor Modulators) can induce prolapse or 
worsen the symptoms. However other studies also indicate that some SERMs 
such as raloxifene taken long-term do not appear to adversely affect urinary 
incontinence or prolapse. 
55  
Reay Jones et al were able to show that the resilience of uterosacral ligaments 
decreases with vaginal delivery and further during the menopause. 85 uteri were 
examined and uterosacral ligament resilience measured. Correlation with 
uterocervical prolapse, patient age, history of vaginal delivery and menopause 
was shown.
56 With weak pelvic floor muscles a decrease in pelvic connective 
tissue resilience related to the menopause could aid progression to symptomatic 
pelvic organ prolapse. Previous studies and clinical experience appear to have 
shown that oestrogen alters the extracellular matrix of different tissues in the 
female pelvic and urogenital tract in stress incontinent women or women suffering 
from pelvic organ prolapse. Further oestrogen can improve the symptoms of 
prolapse and urge or stress incontinence significantly so that imminent surgery 
can be avoided or at least postponed.  46 
 
 
The latest Cochrane review of 28 trials which overall reviewed 2926 women 
assessed the effects of oestrogens used for the treatment of urinary 
incontinence. It was found that oestrogen treatment can improve or cure 
incontinence and the evidence suggests that it is more likely with urge 
incontinence. There were not sufficient data to confirm reliably other aspects of 
oestrogen therapy such as oestrogen type, dose and route of administration.
57 
These effects appear to happen through remodelling of the various components 
of the extracellular matrix, most importantly collagen and elastin. It would be of 
interest is to observe how exactly the expression of the oestrogen receptor is 
changed under the influence of the hormone. Ewies et al showed for example 
that the clearly discernible levels of expression of ER alpha, ER beta, androgen 
receptor (AR) and progesterone receptor (PR) in prolapsed cardinal ligaments 
suggest a relationship to the process of tissue stretch 'trauma', rather than an 
effect of the menopausal status, HRT use or cell proliferation. The use of HRT in 
post-menopausal women appeared to offset some of the changes observed with 
the prolapse.
 58 It was demonstrated that oestrogen receptors were present in the 
vaginal wall and uterosacral ligaments and that the expression of the different 
oestrogen receptors were altered in menopausal women.
59  
 
In the present pilot study using topical oestrogen on prolapsed vaginal wall 
tissue, it was hypothesised that the treatment with direct oestrogen could alter the 
extracellular matrix and perhaps improve symptoms and quality of life of 
postmenopausal women with POP. It was also intended to study molecular 
biology changes that had not been investigated before in vaginal skin of women 
with POP after oestrogen treatment and to determine if such changes were 
progressing towards those required for improving the resilience of vaginal skin. 
This is the first study to examine the changes of extracellular matrix components 47 
 
under the influence of topical oestrogen for a time interval and the first one to 
assess oestrogen receptor α expression in this setting. 
 
 
1.5.5 Smoking 
 
It is known that smoking tobacco influences the biochemical mechanisms of 
blood vessels and physiological functions of connective tissue throughout the 
entire human body. Not only the contained Nicotine, an alkaloid found in the 
nightshade family of plants (Solanaceae) which constitutes approximately 0.6–
3.0% of dry weight of tobacco but other compounds of the most commonly used 
cigarettes and known as carcinogenic, contribute to cardiovascular diseases and 
deterioration of the quality of skin. Previous studies showed that smoking has an 
accelerating effect on the skin aging process.
60 There is further a direct negative 
effect on the elastic fibres in subcutaneous skin tissue resulting in skin laxity and 
reduced elasticity.
61 
 
Araco et al recently showed that smoking increases the risk of post-operative 
complications such as mesh erosions after POP repair where meshes were used 
to enhance surgical outcome.
62 Smoking is now acknowledged as one of the 
main risk factors that contribute to development of POP. This information needs 
to be included in the history of patients of this study and differences between 
smokers and non-smokers need to be statistically assessed.  
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1.6  Extracellular Matrix (ECM) Components of the Pelvic Floor and 
Vaginal Tissue 
 
The adult ECM has the purpose to not only resist tensile forces but also to 
counteract compression. So fibres are required in the ECM that are able to 
achieve both stability and elasticity. The ECM must also provide permeability for 
small molecules to be able to diffuse through the tissue. The ECM contains two 
main components, elastic fibres and collagen. Reticular fibres are also part of the 
tissue but are part of the collagen group. These proteins are produced by 
fibroblasts but collagen can also be synthesised by chondroblasts, osteoblasts 
and smooth muscle cells.
63 
 
 
1.6.1 Collagen 
 
Collagen is the most abundant protein in the adult human body making up 30% 
of the entire protein content.
64 There are various collagen types in existence and 
each of them fulfils a different task in their numerous locations, some being more 
elastic than others. Only the collagen types examined in this study are described 
in more detail. 
 
So far nineteen types of Collagen have been identified and 12 have been studied 
closely. They can be categorised into seven main groups. 49 
 
 
Group 1: Fibrilar collagen 
Type I      composing fibrils in dense and areolar (loose) 
      connective tissue of skin, tendon and bone 
Type II     only in cartilage 
Type III    part of reticular fibres, mainly in loose  
      connective tissue, vessels, uterus, skin 
Type V      very thin fibrils, combined with Type I and III 
   interstitial  tissue  and  vessels 
Type XI     in cartilage, combined with Type II 
 
 
Group 2: Fibril associated collagen  
Type IX     surface of Type II in cartilage 
Type XII    surface of Type I in dense connective tissue 
Type XIV    as Type XII 
Type XVI    location unknown 
Type XIX    embryogenic in brain, eyes and testes 
 
 50 
 
Group 3: Microfibrilar collagen 
Type VI    thin filaments in dense and loose connective tissue 
   and  cartilage 
Type VII    in Skin, anchor protein of the dermo-epithelial  
   connection 
 
 
Group 4: Collagens of basal lamina 
Type IV    in Lamina densa of the basal lamina, part of  
      anchor complex, contains six different alpha  
   chains  in  various  combinations 
 
 
Group 5: Short chain collagen 
VIII      in cornea (Descemet membrane) and  
   subendothelium  of  vessels 
X      cartilage, particularly epiphysis  
 
 
Group 6: Transmembrane Collagen 
XIII      between cellular junctions and cell-matrix junctions 
XVII    in  Hemidesmosomes   
 
 
Group 7: Multiplexin Collagen 
XV      in basal membrane and pericellular matrix 
XVIII    unknown 51 
 
 
 
1.6.1.1 Collagen  I 
 
The most common and most important collagen for tensile strength is Collagen 
Type I.  In skin, 80% of the collagen is type I, where it is responsible for the 
tensile strength of the tissue. Alterations in its gene result in various forms of 
osteogenesis imperfecta and Ehlers-Danlos syndrome type VII which is 
characterized by joint hypermobility and, at the same time, is associated with an 
increased risk of developing pelvic organ prolapse.
65 Together with Type III, IV, 
V, XI it belongs to the group of fibrilar collagens, important collagens in 
connective tissues.  
 
 
1.6.1.2 Collagen  III 
 
 Fifteen per cent of the collagen content in skin is type III which is accountable for 
elasticity of tissues. The ratio between collagen I and III demonstrates the 
characteristics of the tissue. A higher ratio shows that the tissue is more tensile, a 
lower that the tissue is more elastic.
66 Alteration of the ratio has been found in 
women with stress incontinence.
137 
 
 
1.6.1.3 Collagen  XVII 
 
Collagen XVII is a collagenous transmembrane collagen. It is composed of an 
alpha-chain which contains an N-terminal intracellular domain, a hydrophobic 
transmembrane area and a larger, extracellular C-terminus. Collagen XVII is a 52 
 
structural constituent of the hemidesmosomes. Hemidesmosomes arbitrate 
adhesion of the epidermal keratocytes and other epithelial cells to the underlying 
basal membranes. Collagen XVII is involved in the maintenance of the epithelial 
cell adhesion through multiple protein–protein interactions. This is demonstrated 
especially through genetic and acquired skin diseases. The lack or loss of 
collagen XVII function leads to diminished epidermal adhesion and skin blistering. 
Collagen XVII is shed from the cell surface yielding a shorter soluble form of the 
molecule by proteinases of the ADAMs family (ADAM-9 and ADAM-10). The 
functional consequences of shedding of collagen XVII are not yet clear
67, 
68 It is 
important to give insight into the basic construct of the collagen fibres to 
understand the function appropriately. 
 
 
1.6.1.4  Structure and molecular construction of Collagen 
 
Collagen is mainly produced by fibroblasts of connective tissue and released into 
the extracellular matrix. Collagens are arranged by collagen fibrils which are 
between 30-70 nanometres wide. Collagen fibrils are usually composed in the 
shape of a triple helix, in case of collagen type I it is an assembly of two alpha1 
and one alpha2 chain. These chains are arranged in the procollagen fibre which 
is then shortened to tropocollagen (Figure 1.8). Tropocollagens are arranged 
adjacent to each other overlapping the neighbouring molecule by a quarter of its 
length thus giving the typical electromicroscopic picture of steps (Figure 1.9). 53 
 
Pictures of collagen molecules and fibrils  
 
 
Figure 1.8 Collagen Type I molecule. Two α1-chains (white) and one α2-chain 
(grey) building a triple helix 
 
 
 
 
Figure 1.9 Molecular structure of collagen fibrils. tropocollagen (arrows) is 
overlapping the adjacent molecule by ¼. (schematic by Benninghoff ) 
 
All collagens contain a high amount of the aminoacids glycine, proline and 
hydroxyproline. Glycine is in each third position of the molecule and is essential 
for creating the structure of the triple helix. Mutations that interfere with this 
arrangement are responsible for various diseases.  
 
The alpha helices of procollagen are constructed in the endoplasmatic reticulum 
of fibroblasts. One important step for the synthesis is the hydroxylation of proline 
through proline hydroxylase which requires Vitamin C as a co-factor. Thus 54 
 
Vitamin C deficiency can lead to insufficient collagen synthesis and scurvy. 
Lysine is also hydroxylated besides proline and further oxidised to an aldehyde 
formation through lysyloxidase which  requires copper as a co-factor. Procollagen 
is 10-15 nanometre longer than tropocollagen. It is spliced by procollagen 
peptidase removing the propeptides at the C- and N-terminals. 
 
The lysine aldehyde groups of the final tropocollagen arrange the molecule 
through covalent connections that support a stable structure and stabilisation of 
the fibrils. These cross-links between the molecules are initially divalent dehydro-
hydroxylysino-norleucine (Δ-HLNL) and hydroxylysino-keto-norleucine (HLKNL). 
With maturity of the tissue they are converted to more stable trivalent cross-links, 
histidino-hydroxylysino-norleucine (HHL) and hydroxylysylpyridniline (pyrid) 
respectively.
69 There is a high turnover of collagen fibres and fibrils. For example 
Type I collagen the half-life in gingiva of rats is 2-3 days.
70 Mechanical strain and 
demands are a main stimulus for synthesis and turnover. 
 
 
1.6.1.5  Degradation of Collagen 
 
 
The main group of enzymes breaking down collagen are the matrix 
metalloproteinases (MMPs). (see MMP section later) 
 55 
 
 
1.6.2 Elastin  Fibres 
 
Elastin is another central protein in the connective tissue and extracellular matrix 
of the human body. Its function is mainly to provide elasticity in tissues where 
tensile strength is not solely required and would challenge function. It is an 
amorphous protein, mainly composed of the amino acids glycine, valine, alanine 
and proline. In contrast to collagen it lacks hydroxyproline and hydroxylisine. It is 
found in oxytalan, elaunin and elastic fibres which are part of the elastic 
network.
71  
 
The Elastin gene lies on the long arm of chromosome 7 and codes the precursor 
molecule of elastin, tropoelastin. The genome is largely decoded and it was found 
that functionally distinct hydrophobic and cross-linking domains of the protein are 
segregated into separate exons throughout the gene. All exons are multiples of 
three nucleotides, and exon-intron borders always split codons in the same way 
which permits cassette-like alternative splicing. It is further known that 
transcription is initiated at multiple sites in the gene.
72 Extensive homology of 
amino acid sequence exists among the mammalian species and there is in 
addition strong conservation of nucleotide sequences in the 3' untranslated 
region of the gene. Variations in the structure of mRNAs resulting from alternative 
splicing could explain the existence of the multiple forms of tropoelastin observed 
electrophoretically in several species. Different kinds of splicing patterns could 
occur in human populations and may contribute to aging and pathological 
situations in the cardiovascular and pulmonary systems.
73 
 
 Tropoelastin is rich in lysine and contrary to elastin it is soluble. It is deposited in 
a net of fibrillin-rich microfibrils.
74 In a further step it is oxidized by lysyl oxidase to 56 
 
produce insoluble, durable cross-linked arrays. Mature elastic fibres are a 
composition of a microfibrillar covering and an inner centre of amorphous 
crosslinked elastin. The distribution of microfibrils in dynamic elastic tissues such 
as blood vessels, lung, ligaments and skin is essential for the tissue function.
75 
The description of the native relaxed state of the protein in terms of trans-
conformational balance between extended and folded structures was previously 
proposed 
76 and recent studies support this view. The same polypeptide 
sequences have been analysed for their ability to self-assemble. The majority of 
them were able to adopt more or less organized structures. On the whole, the 
results obtained gave significant insight to the roles played by specific 
polypeptide sequences in self-assembly and possibly in elasticity.
77 
 
Fibrillin-1 mutations cause Marfan syndrome, which is associated with 
cardiovascular, ocular (ectopia lentis) and skeletal defects. Fibrillin-2 mutations 
cause congenital contractural arachnodactyly (CCA) with overlapping skeletal 
and ocular symptoms and elastin mutations cause Williams syndrome, 
supravalvular stenosis (SVAS) 
78 and cutis laxa.
79  
 
Elastic fibres are designed to maintain elastic function for a lifetime.
80 But various 
enzymes, matrix metalloproteinases and serine proteases, are able to cleave 
elastic fibre molecules.
81 The degradation is part of the physiological aging of 
human tissues with subsequent loss of elasticity and flexibility. It plays an 
important role for the incidence of degenerative changes in sun damaged skin
82, 
the occurrence of emphysema or aortic aneuryism 
83 and also pelvic floor 
dysfunction.  
 
Barros et al examined human cervical interspinous ligaments and showed that 
aging induces structural changes to elastic and collagen fibres in this structure. 57 
 
An age-related progressive increase in collagen and mature and elaunin elastic 
fibres was reported but elastic fibres showed structural degenerative changes 
with aging. Oxytalan elastic fibres were decreased.
84 This physiological process 
is confirmed by many studies. It seems though that elastin and collagen 
degradation can be influenced or altered by hormones once the process has 
been initiated through strain, trauma or stretching as would be the case in pelvic 
organ prolapse or stress incontinence. 
 
 
1.6.3  Matrix Metallo Proteinases (MMP) 
 
Matrix Metalloproteinases (MMPs) are zinc-dependent endopeptidases. They are 
catalysts of proteolytic events in normal as well as in pathological tissue. There 
are two main groups, gelatinases and proteinases which can further be broken 
down into subgroups. MMPs are important for cell migration, bone elongation, 
wound healing, angiogenesis
85, and many more tasks in the extracellular matrix 
of various different connective tissue structures from skin to bone. Pathological 
processes are tumour growth and migration, fibrosis, arthritis, lupus, 
scleroderma, cirrhosis, multiple sclerosis, aortic aneurysms, infertility, and many 
more diseases. They are involved in many processes, including tissue 
remodelling and also modification or release of biological factors. Substrate 
specificity for the MMPs is not yet entirely known. Known substrates include most 
of the extracellular matrix components (e.g. fibronectin, vitronectin, laminin and 
tenascin). Similary, proteinase inhibitors such as a1-proteinase inhibitor, 
antithrombin-III and a2-macroglobulin are selectively cleaved by MMPs as are 
growth factors such as IL-1a and pro-TNF-a, IGF binding protein-3 and IGFBP-
5.
86 
 58 
 
 
1.6.3.1 Gelatinases 
 
The gelatinases are MMPs number 2 and 9. They cleave mainly Type IV collagen 
and gelatine and can be distinguished by different molecular structures at the 
catalytic domain. The gelatine binding region is positioned close to the zinc 
binding area and forms a separate folding unit which does not interfere with the 
catalytic domain. The most commonly used substrate to study MMP2 and 9 
activities is gelatine (heat denatured collagen).  
 
 
1.6.3.2 Collagenases 
 
All known collagens (Types I - XIV) are substrates of different MMPs. The 
collagenases are capable of degrading triple-helical fibrillar collagens into 
distinctive 3/4 and 1/4 fragments. Collagens are the major components of bone 
and cartilage, and MMPs are the only known enzymes in mammals that are able 
to degrade them. Collagenases are MMP 1, 8, 9, and 13. Type I collagen has 
been used as a substrate for some MMPs in research settings.  It is cleaved at 
the same site on all three strands, releasing ¼ and ¾ length fragments. MMP-1 
cleaves intact triple helical collagen efficiently, but does not work well on other 
substrates. MMP-3 and MMP-7, cleave a broader range of substrates but for 
most of the MMPs, the substrate specificity in vivo is so far ill defined.  59 
 
 
1.6.3.3 MMP2 
 
MMP2 is described by the National Library of Medicine - Medical Subject 
Headings (MeSH) as a secreted endopeptidase. It has homology with interstitial 
collagenase but possesses an additional domain which is similar to fibronectin.  It 
is 72-kDa in size and belongs to the group of gelatinases. MMP2 particularly 
degrades type IV collagen
87 but also cleaves collagens that are previously 
processed by other MMP. (e.g. MMP1) Mutations in its gene have been 
associated with Winchester syndrome which is a disease featuring symptoms of 
pathologic changes consisting of dwarfism (resulting from disturbances of the 
skeletal-articular system), corneal opacities, coarsening of facial features, 
leathery skin, and hypertrichosis.
88 
 
 
1.6.4  Other Proteins of the Extracelluar Matrix 
1.6.4.1 Proteoglycans 
 
The characteristic of proteoglycans which also gives this family of proteins their 
name is their structure. They are composed of a core protein with one or multiple 
glycosaminoglycan (GAG) side chains. These glycosaminoglycan chains can 
contain different carbohydrate complexes such as chondroitin or dermatan 
sulphate, heparin sulphate or keratan sulphate. The protein core remains similar 
in all groups. Proteoglycans are an important component of extracellular matrix. 
They form complexes with other proteoglycans, hyaluronate (Aggrecan and 
Versican) and proteins such as collagen (e.g. Fibromodulin, Decorin, Biglycan) or 
Laminin and Fibronectin (Perlecan).
89 They maintain hydration through binding 60 
 
cations (sodium, potassium and calcium) and water and also regulate the 
movement of molecules around them. They further influence adhesion, migration 
and proliferation of cells.
90, 
91 
 
 
1.6.4.2 Glycoproteins 
 
Opposite to proteoglycans, glycoproteins contain only short carbohydrate chains 
that do not contain sulphur, glucornic or idurinic acid. They function as anchoring 
molecules of cells in the extracellular matrix. Fibronectin is mainly found in its 
dimeric form in blood serum or on cell surfaces in the ECM. It provides the 
connection of cells to collagen in tissues that do not possess a basal lamina and 
also binds to integrins. Mouse experiments have shown that knocking out the 
genetic information is lethal. 
 
Vitronectin is similar to fibronectin but in addition is found to bind to elastic fibres. 
It is further a component of the coagulation system in serum. Laminins are 
constructed by three protein chains (α, β, γ) which can assemble to compose 11 
types of laminin molecules. Laminins polymerise to form a network and so give 
stability. Several types can adhere to collagen type IV through nidogen proteins 
and hence attach to the lamina densa. Glycoproteins are essential for various 
developmental and differential processes. Genetic abnormalities lead to 
significant diseases as junctional epidermolysis bullosa or severe muscle 
dystrophy. 61 
 
1.7  Changes of the Pelvic Floor and Vaginal Skin in Pelvic Floor 
Dysfunction 
 
Many previous studies were able to show changes in the tissue of the pelvic floor 
or vaginal skin of stress incontinent women or women with POP. Changes in 
collagen remodelling, elastin turnover or expression of other extracellular matrix 
proteins were discussed and investigated. Alperin et al showed in a summary 
from 2006 that the vagina and its support tissues actively remodel in response to 
different environmental stimuli. Not only the synthesis of those structural proteins, 
but also the balance between the activity of the major proteolytic enzymes that 
degrade them and the inhibitors of proteolysis are important for remodelling 
tissue to maintain normal function.
92 Bakas et al assessed the procollagen 
production for collagen I and III in sixty eight women with genuine stress 
incontinence and compared these to controls. They found that the quantity of 
collagen type I and III was significantly reduced in patients with stress 
incontinence. The possible cause for the reduction in the amount of collagen in 
women with GSI could be attributed to either a disturbance in the translation of 
mRNA to protein (collagen) or increased catabolism of collagen by its 
collagenase.
93  
 
Chen et al showed that stress incontinent women demonstrated an increase in 
MMP-1 mRNA expression and a decrease in the inhibitor TIMP-1 mRNA 
expression. These findings are consistent with increased collagen breakdown.
94 
However it was also shown that there was no difference in TIMP-2, TIMP-3, 
MMP-2 or MMP-9 mRNA expression between stress incontinent women and 
controls. Chen et al examined further, in different studies, the effect of oestrogen 
on vaginal tissue fibroblasts and compared cells from incontinent to cells from 
continent women. The concentrations on metalloproteinase and tissue inhibitors 62 
 
of metalloproteinase protein expressions in cultured pelvic fibroblasts were 
measured. The study showed that periurethral vaginal tissue inhibitors of 
metalloproteinase (TIMP) expression from fibroblasts of continent women 
significantly increased with increasing oestradiol concentrations (0-100 pg/mL, 
P<.05) differing to fibroblasts of incontinent women in which no such effect could 
be demonstrated. Neither group showed a change in metalloproteinase 
production in response to varying oestrogen levels. These results suggest 
oestrogen influences collagen degradation in continent women by increasing 
TIMP production. Also it appears to have a reduced inhibitory effect on 
collagenolysis in women with stress urinary incontinence.
95 A recent study by 
Karam et al examined elastin expression and fibre width in the anterior vaginal 
wall of postmenopausal women with and without prolapse. They found that 
elastin expression and fibre width were significantly lower compared to controls of 
a similar age without prolapse. No significant differences were detected when 
examining smoking habits, parity, HRT use and BMI.
96 In another recent study 
Söderberg et al examined vaginal skin from 15 women with POP and measured 
collagen I, collagen III, fibrillin-1, fibulin-5, decorin, lumican and fibromodulin 
(leucine-rich repeat proteoglycans {SLRPs}) RNA expression. There was 
substantially altered gene signal for production of SLRPs, which are regulators of 
collagen and elastic fibre assembly. They found that decorin and lumican mRNA 
expression were increased 16 and 8 fold respectively in premenopausal women 
with POP compared to controls. Fibromodulin and fibulin expressions were 
significantly lower compared to controls.
97 
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1.8  Oestrogen Receptors and Metabolism  
 
Oestrogens belong to the group of steroid hormones. They are the primary 
female sex hormones. Like all steroid hormones they derive from cholesterol and 
classically readily diffuse across the cell membrane inside the cell where they 
interact with oestrogen receptors.
98  
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Figure 1.10 schematic Development of Oestrogen and Testosterone 64 
 
 
   
Figure 1.11 Pathway of Interaction of Oestradiol and Oestrone 
 
The natural oestrogens are 17β-oestradiol (E2), oestrone(E1) and oestriol(E3). They 
are C18- steroids which do not have an angular methyl group attached to the 10 
position or a Δ
4–3- keto configuration in the A ring. Oestrogens in the female 
human are mainly secreted from ovarian granulosa cells of the follicles, the 
corpus luteum and placental tissue in pregnancy. The most important human 
oestrogen is 17β-oestradiol. It is converted from testosterone through the enzyme 
aromatase. The same enzyme converts androstendione, another C19 steroid 
hormone, into oestrone. 
 
2 percent of secreted oestradiol remains free in the blood stream while the rest is 
bound to albumin (60%) and gonadal steroid binding globulin also known as sex 
hormone binding globulin (38%). All oestrogens are degraded via a liver pathway 
and eventually secreted in the urine as glucuronide and sulphate conjugates. 
Some is reabsorbed as part of the enterohepatic circulation. 65 
 
 
Oestrogen has a distinct influence on the skin. Some studies have been able to 
demonstrate that oestrogen can prevent skin ageing to a certain extent. It 
increases the water holding capacity, enhances epidermal barrier function and 
shows a decrease of the alteration of skin elasticity found with time
99. Related 
studies showed that postmenopausal abdominal skin areas that received 
hormonal treatment with application of Estrogel cream 1.5 mg/day 
percutaneously for 1 yr, showed significantly increased collagen content (p< 
0.001). There was a strong correlation between the change in skin collagen 
content and the original skin collagen content. This indicated that the change in 
collagen content in response to oestrogen therapy is dependent on the original 
level. There is no further increase once an 'optimum' skin collagen level has been 
reached. 
100 A national multicenter cohort study performed by Dunn, LB et al 
1997 including 3875 postmenopausal women demonstrated that oestrogen use 
prevents dry skin and skin wrinkling, thus extending the potential benefits of 
postmenopausal oestrogen therapy to include protection against selected age- 
and menopause-associated dermatologic conditions
101. 
 
Another study was able to show that locally applied oestrogens on abdominal 
skin of menopausal women enhanced the structure and content of elastic fibres 
compared to controls.
102 No significant changes were observed in the epidermal 
cell size, mitotic activity, dermal vascularization or inflammatory infiltrate between 
the specimens taken before and after the treatment or between the treatment 
groups. But not only does oestrogen affect the healthy skin and influences skin 
changes of physiological ageing it also influences healing capacity and so could 
be of importance in the direct post-operative phase after a prolapse repair. 
Ashcroft et al studied the influence of oestrogens on scar healing and 
inflammatory effects on the cutis and found that topical oestrogens increase the 66 
 
extent of wound healing compared to placebo, with a decrease in wound size, 
increased collagen levels and increased fibronectin levels. Also oestrogen 
enhanced the strength of the wound tissue after 80 days. A decrease in wound 
elastase levels secondary to reduced neutrophil numbers, and decreased 
fibronectin degradation was found as well. It appeared that oestrogen directly 
inhibited neutrophil chemotaxis and altered expression of neutrophil adhesion 
molecules.
103 Delays in wound healing could be significantly diminished by topical 
oestrogen. The healing capacity of non-keratinized epithelium is larger and the 
healing process faster compared to keratinized skin. Also, non-keratinized skin is 
able to absorb oestrogen to a bigger extend as barrier components are not as 
extensive as in epidermis. The effect of topical oestrogen could therefore even be 
enhanced in vaginal tissue that is dealing with scarring.  
 
Previous studies looking more specifically into changes in female pelvic fascia 
and vaginal skin tissue have shown that oestrogens have considerable influence 
on the cardinal ligaments and vaginal skin. Pubocervical fascia fibroblasts 
showed increased proliferation capacity after 17β-oestradiol treatment when 
compared to skin fibroblasts.
104 Philips et al demonstrated that vaginal skin 
resembles endopelvic fascia
105 demonstrating a correlation in expression of pro-
MMP-2, activated MMP-2, MMP-9 and TIMP-2 in vaginal tissue with tissue in the 
uterosacral ligaments. These are specific markers of collagen metabolism in the 
vaginal and uterosacral tissues and it suggests that vaginal tissue reflects 
changes occurring in the endopelvic fascia. The changes, which were more 
pronounced in vaginal tissue, may be a result of the prolapse rather than cause. 
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1.8.1  Oestrogen Receptors and Distribution 
 
Oestrogen receptors are nuclear receptors (NR) and are part of a superfamily of 
ligand activated transcription factors that modulate specific gene expression. 
There are more than 100 nuclear receptors identified. They are categorized into 
steroid receptor subfamilies: 
 
Class I NR -classically defined as ligand dependent and will homodimerize, Class 
II NR -classically defined as ligand independent with potential for both homo- and 
heterodimerization. The oestrogen receptor (ER) is classified as a Class I nuclear 
receptor. It is only activated through interaction with oestrogen and oestrogen like 
molecules. Classically, in the absence of oestrogen, ER is embedded within the 
nuclei of target cells and maintained in an inactive state. Binding of oestrogen or 
similar ligand induces a conformational change of the ER. Changed like this, the 
ER undergoes homodimerization and shows high-affinity to specific sites on 
DNA- oestrogen response elements (EREs). Once the oestrogen-receptor 
complex is bound to DNA, it regulates the expression of oestrogen-responsive 
genes. 
 
More recently the oestrogen receptor has been found also to have non-genomic 
actions and can be membrane associated and linked to signal transduction 
mechanisms. Some of the rapid effects of oestrogens that are too fast to be by 
genomic action are attributed to this. Non-genomic actions, which are initiated at 
the cell membrane, also appear to impact transcription. There is good evidence 
that the membrane-limited actions of hormones such as oestrogens, involve the 
rapid activation of kinases and the release of calcium. These (non-genomic) 
effects have been attributed in some cases to receptors different to those 
mediating gene transcriptions but most evidence indicate that they result from the 68 
 
activity of a population of nuclear receptor molecules acting outside the cell 
nucleus.  
 
Studies on oestrogen and vitamin D receptors suggest that non-genomic and 
genomic effects may integrate in a unique mode of action of nuclear receptor 
ligands, in which the non-genomic effects compose signalling pathways required 
for the effects at the genome level.
106 Prior to this Vasudevan et al showed in 
2008 that membrane actions of oestrogens, which activate rapid signalling 
cascades, can also potentiate nuclear transcription in both the central nervous 
system and in non-neuronal cell lines. These signalling cascades may occur in 
parallel or in series but subsequently, converge at the modification of 
transcriptionally relevant molecules such as nuclear receptors and/or 
coactivators.
107  
 
 
1.8.2  Two Isoforms of ER 
 
Initially it was believed that oestrogen only binds to a single receptor, now 
referred to as ER-α. But in recent years a second oestrogen receptor was 
identified and named ER-β. The two receptors share common structural and 
functional domains. They bind oestrogen similarly and cause a similar response 
once activated. But there are differences not only deriving from structure and 
transcriptional activities but most importantly for this study, in tissue distribution.  
 
ERα (NCBI-OMIM) is mapped to the long arm of chromosome 6. It contains 595 
amino acids with an N-terminal modulating domain, central DNA-binding domain 
(DBD) and a C-terminal ligand-binding domain (LBD). 
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ERβ (NCBI-OMIM) is mapped to band q22-24 of chromosome 14. It is shorter 
than ERα with 530 amino acids.  
The functional domains are the same but it is short of a portion in the C-terminal 
domain which is important for the effects for certain anti-oestrogens. The regions 
of highest homology between the two receptors are the DBD (>95%) and the 
LBD (>55%)
108.  
 
 
1.8.3  Mechanisms of ER Signaling 
 
It is now known that ERα and ERβ not only homodimerize but can also 
heterodimerize. In addition, new mechanisms for ER activation have been 
delineated which adds to the complexity of oestrogen receptor signal 
transduction. Hormone dependent phosphorylation is suspected to be an 
important aspect of ER binding to specific response elements. Oestrogen 
receptor subtypes can regulate transcription through AP-1 response elements 
through direct interaction with AP-1 transcription factors c-fos and c-jun. Cross 
talk between different signaling pathways can also induce ER activation. 
Receptor tyrosine kinases and IGF receptors can indirectly activate ER through 
direct phosphorylation of specific residues. Conformational changes in ER 
structure, determined by specific ligand binding, expose different amino acids that 
are critical for binding to protein factors involved in targeted transcriptional 
activation.  
 
Finally, ER alone does not direct gene expression. Cellular pools of co-regulatory 
proteins play an integral role as signaling intermediates in enhancing or 
repressing transcriptional activity. Generally, co-activators have intrinsic histone 
acetylation activity associated with increased transcriptional activity and co-70 
 
repressors possess deacetylase activity which represses gene activity by keeping 
chromatin in a more condensed state. 
109, 
110 
 
In the present study, presence of ERα and any change in expression in response 
to oestrogen was of interest. For it was previously demonstrated that there is a 
link between changes in oestrogen receptors in cardinal ligaments of prolapsed 
uteri and that of vaginal tissue
105. A.A. Ewies undertook a study to evaluate the 
differential expression of gonadal steroid receptors in human cardinal ligaments 
of prolapsed uteri and compared it with non-prolapsed controls. The use of HRT 
was significantly associated with low androgen receptor and high progestogen 
receptor expression. However, increased expression of ERα and ERβ in the 
prolapsed cardinal ligaments appeared to happen because of tissue trauma after 
considerable stretching, rather than an effect of the menopausal status, HRT use 
or cell proliferation. Importantly, the use of HRT in post-menopausal women 
appeared to counterbalance some of the changes observed within the prolapsed 
tissue. 
58 Mokrzycki ML et al found the presence of oestrogen receptors in the 
cardinal ligaments and hypothesised that an increase in steroid receptors could 
improve pelvic floor support.
111 Ulmsten suggested that the existence and 
relevance of ER alpha receptors in both the pelvic floor muscles and the round 
ligament suggested that this could be a scientific basis for a possible beneficial 
effect of oestrogen therapy and a complement to other therapies, in prolapse and 
urinary incontinence.
112, 
113 Zhu L et al established that in the levator ani and 
connective tissue of postmenopausal women with POP the ER alpha content was 
significantly higher than in controls
114, while Copas et al showed that there was a 
significant increase in ER alpha expression in levator ani fascia of symptomatic 
patients without HRT when compared to asymptomatic age-matched women. 
Further, he demonstrated that ER alpha expression was significantly lower in 
postmenopausal symptomatic women receiving long-term oestrogen replacement 71 
 
compared to matched women without HRT. Long-term oestrogenisation 
decreased significantly ER alpha expression.
115 
 
Different findings could be explained by small numbers in these studies not 
offering enough data and the lack of a useful Meta-analysis. Laborda at al 
showed in 2004, that the tissue sampling site of prolapsed vaginal tissue is 
markedly important. Stretched vaginal tissue showed different expression and 
content of extracellular matrix proteins compared to tissue that was involved in 
the prolapse but not stretched. Stretched tissue appeared not to be able to 
change or process the influence from topical hormones and therefore was not 
suitable for analysis.
36  
 
Prolapsed vaginal wall tissue has so far not been examined to show changes in 
expression or content of ERα. Fu. X and Ulmsten in 2003 did not look at 
prolapsed vaginal wall tissue but tissue of stress incontinent postmenopausal 
women ERα was detected in vaginal epithelial, stromal and smooth muscle cells. 
It was significantly more frequent in stress incontinent women compared with 
controls. ERα was not observed in vaginal blood vessels while ERβ was detected 
in epithelial and vascular smooth muscle cells of the vagina. The expression of 
ERα, but not of ERβ, in menopausal stress incontinent women was regulated by 
oestrogen or progestin replacement therapy
 116. 72 
 
 
 
 
 
1.8.4   Selective Estrogen Receptor Modulators (SERMS) 
 
Selective Estrogen Receptor Modulators (SERMs) are known for their beneficial 
effect on oestrogen sensitive tissues and are used widely in different specialities 
such as Orthopaedics, Urology, Breast Surgery and Gynaecology. Many are 
commonly used for medical treatment of e.g. osteoporosis, breast or other 
gynaecological cancer and other various gynaecological disorders. SERMs 
include a relatively large number of compounds, each with different profiles of 
oestrogenic or anti-oestrogenic actions on the genital tract so they are partial or 
pure receptor agonists or antagonists. Their action can be different in various 
tissues, and therefore they have the potential to selectively inhibit or stimulate 
oestrogen-like action differently in different tissues.  
 
Breast 
Bladder 
Trigone 
Bone 
Cardiovascular 
Stystem 
 
Oestrogen 
Vaginal mucosa, 
pelvic fascia, 
uterosacral 
ligaments  Uterus with 
myometrium, 
endometrium and 
cervix 
Figure 1.12 Sites of action of oestrogen and oestrogen receptors 73 
 
 
SERMs, which inhibit breast and prostate response to oestrogens while providing 
oestrogen-like stimulation of bone, brain, and potentially the cardiovascular 
system, are already available. But so far there are no SERMs that suppress hot 
flushes in postmenopausal women without stimulating uterine growth. SERMs 
that do not stimulate mammary alveolar proliferation could be used for the 
treatment of endometriosis.
117  
 
Animal studies examined the influence of SERMS in comparison with oestrogen 
on variant tissues and cells. It was found that oestrogen regulated also different 
genes compared to SERMs, especially those genes associated with catalysis and 
metabolism. Genes associated with matrix integrity were also differently 
regulated by oestrogen and SERM, for example raloxifene. Oestradiol and 
lasofoxifene elevated MMP2 activity in rat uterus to twice that of raloxifene. 
Levormeloxifene stimulated MMP2 up to 12x that of raloxifene. There are 
significant differences between oestradiol and raloxifene in influencing uterine 
regulation of genes and proteins associated with matrix integrity. This may be a 
potential key difference between the actions of SERMs in the uterus of 
postmenopausal women.
118 These findings could also be important for pelvic 
floor components where SERMs and oestradiol act at similar sites and influence 
the extracellular matrix but different SERMS might enhance or alleviate pelvic 
floor dysfunction.  
 
Recent studies looked more closely at human skin fibroblasts from post-
menopausal women and studied effects of oestradiol and raloxifene on collagen 
biosynthesis. These studies showed that both, oestradiol and raloxifene 
increased mRNA expression of ERα compared to controls. Raloxifene had a 
greater effect on collagen biosynthesis than oestradiol and was found to inhibit 74 
 
expression of MMP-9.
119 These findings are in contrast to other studies such as 
that of Ewies et al and thus further investigations are necessary to establish the 
action and effect of SERM versus oestradiol in human skin, vaginal skin and 
other pelvic floor components. Further knowledge could establish the therapeutic 
or preventative use of SERM for pelvic floor dysfunction. 
 
 
1.8.4.1  Review of Oestradiol and different SERM Action on various Tissues 
as known so far: 
 
Oestradiol  
Uterus:  
 proliferation  of  endometrium 
Extracellular matrix:   
  decreases MMP2, MMP9 and TIMP expression 
  increases MMP7 expression 
Skin: 
  lowers pH and increases permeability 
Breast: 
  induces cell proliferation  
Bone: 
  increases bone density   
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Raloxifene 
Uterus: 
  neutral or mild anti-oestrogenic effect on endometrium 
Extracellular matrix: 
  MMP2 and MMP7 activity increased 
  no effect on MMP9 
Vessels: 
  Induction of NO enhanced re-endotheliasation  
  risk of thromboembolism 
 
Tamoxifen 
Uterus: 
  increased growth of fibroids, increased cell proliferation on  
  endometrium (cave – endometrial cancer) 
Extracellular matrix: 
  no known effect on MMP9 
Vessels: 
  increased NO enhanced re-endotheliasation 
Ovary: 
  increased cyst formation on ovary 
Breast: 
  acting cytotoxic and antioestrogenic  
Bone: 
 inhibiting  osteoclasts 
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Levormeloxifene 
Uterus:  
  increased endometrial proliferation 
Extracellular matrix: 
  increasing MMP2 activity 12x more than Raloxifene 
Bone: 
  decreased bone turn over 
 
 
1.8.5  SERM Effect on Pelvic Floor 
 
It was shown that the incidence of POP during the use of the SERM 
levormeloxifene and idoxifene, rose 30 times higher than in controls. Pelvic organ 
prolapse was reported as an adverse event associated with both drugs.
120 
Albertazzi et al compared different studies of the different effects of SERMs on 
stress incontinence and pelvic organ prolapse. The aim of this review was to 
systematically evaluate available data from randomized, controlled studies. Both 
Tamoxifen and Raloxifene seemed to increase the incidence of pelvic floor 
prolapse in one trial while Raloxifene did not appear to increase the incidence of 
urinary incontinence. Levormeloxifene and Idoxifene though were noted to 
increase uterine prolapse and incontinence during phase III trials. Ewies et al 
found that the application of cell stretch damages the F actin configuration within 
the cells, but impressively levormeloxifene increases the frequency and severity 
of these abnormalities.
121 Vardy et al were also able to show that neither 
raloxifene nor tamoxifen improved cytohormonal effects in the vagina or urethra 
compared with conjugated equine oestrogen. In addition raloxifene and tamoxifen 
appeared to show worsening prolapse compared with conjugated equine 
oestrogen and placebo. 
122 77 
 
 
On the other hand, in a study by Parsons A et al, it was observed that either the 
topical use of oestradiol containing cream or nonhormonal moisturiser in women 
suffering with vaginal atrophy could be used in combination with raloxifene. There 
was no lesser effect of oestradiol when given together with raloxifene. Oestradiol 
containing cream improved the signs of atrophy but not the symptoms compared 
to nonhormonal cream in combination with raloxifene.
123 
 
 
1.9  Vagifem® and Other Pharmacological Oestrogens 
 
Vagifem® is a vaginal oestrogen pessary which was to be used in the present 
study to demonstrate the effects of oestrogen on prolapsed vaginal tissue. 
Vagifem contains 25micrograms of 17β-oestradiol per tablet and is an easy to 
apply system. It is licensed in the UK to treat atrophic vaginitis for 
postmenopausal women. Like other topical oestrogen supplements it was thought 
to be useful in improving symptoms of other urogenital problems like POP or 
stress incontinence. The recommended dose in the BNF is 25 micrograms (1 
pessary tablet) daily for fourteen days and then 25micrograms twice weekly for 
three months. The latter treatment can be increased to six months if required. 
Vagifem was used for this study as it was found to be used with a greater 
compliance compared to other topical oestrogens as creams or other pessaries. 
Other than systemic HRT preparations the side effect profile for Vagifem® is low 
but effects on the endometrium with long term treatment are uncertain.  
 
Studies assessing the risk of malignancy during the usage of Vagifem® or other 
low potency vaginal oestrogens, showed though that vaginal oestrogen had no 
significant increased relative risk of endometrial neoplasia or atypical hyperplasia, 78 
 
which is a premalignant or early malignant lesion.
124 However there were no 
details on the time frame in which the oestrogens were administered. The 
difference in action between orally taken oestrogens and vaginally applied 
oestrogens is found in the absorption and transportation of the hormones. Orally 
applied oestrogen is conjugated proficiently in the liver
125 but it does not bind well 
to gonadal steroid hormone binding globulins and therefore most of the serum 
oestrogen is in its active form. With oral application on a daily base the possibility 
of accumulation in the blood stream is high and so reaction of endometrial cells 
probable. Absorption of vaginal oestrogen, though it appears to be absorbed 
easier initially, decreases over the time with increasing thickness of the vaginal 
wall due to its effects. 
126 Further, it was shown in this study by Nilsson et al that 
serum oestrone and gonadotrophin levels were unaffected during treatment. 
Clinical and subjective improvement was apparent and acceptance of treatment 
was good. 
 
 
1.9.1  Hormone influence on pelvic connective tissue in stress 
incontinence or prolapse 
 
Chen et al examined fibroblasts from periurethral vaginal tissue of stress 
incontinent women in the secretory and proliferative phase of the cycle. It 
appeared that relaxin enhances elastolytic activity in stress urinary incontinence 
cells. It decreases the expression of alpha-1 antitrypsin and increases the total 
elastase activity in proliferative phase cells while increasing the total elastase 
activity in secretory phase cells. Fibroblast total elastase activity was inhibited by 
increasing concentrations of alpha-1 antitrypsin.
127 Relaxin is a peptide hormone 
and belongs to the insulin super family. It is produced by the corpus luteum of the 
ovary and during pregnancy by the placental tissue. The exact purpose of relaxin 79 
 
in the female is not yet determined but it is mainly expressed in the luteal phase 
of the cycle diminishing if no pregnancy occurs and menstruation sets in. This 
could show a relation to hormonal influence on connective tissue in stress 
incontinent women.  
 
Other studies fitting with these findings are again by Chen in 2003. This time the 
direct influence of oestrogen on protein expression by vaginal tissue fibroblasts of 
stress incontinent women was assessed. Findings were that TIMPs were 
decreased in tissue from incontinent women but no more dramatic oestrogen 
influence was noted. Fibroblasts from continent women showed a significant 
increase in TIMP expression with oestrogen. MMP2 expression was neither 
altered in incontinent women or controls.
128 Even though the influence of 
oestrogen on tissue from incontinent women could not be demonstrated it was 
effective in tissue from continent women. It could be possible that cellular 
manipulation prevented any response. Altogether, there is convincing evidence 
that a relation to hormonal influence on connective tissue in stress incontinent 
women exists. 
 
 
1.10  Quality of Life 
 
Pelvic organ prolapse has a significant impact on the quality of life. There is a 
large range of symptoms and women suffering from prolapse often seek help and 
advice initially because of these. It is rather difficult to establish how large the 
impact of these symptoms is on the normal quality of life. The King’s Health 
questionnaire was developed to assess quality of life more accurately and give 
the possibility of a better subjective analysis. 
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It was developed by Digesu et al. and published in 2005.
129 The validity and the 
internal reliability showed good statistical outcomes. The test-retest reliability 
confirmed a highly significant correlation between the total scores for each 
domain. The P-QOL questionnaire for English-speaking patients was proven to 
be reliable and valid. Since then it was translated and tested in various non-
English speaking countries and was found to be a consistent and valid instrument 
for assessing symptom severity, impact on quality of life in women with 
uterovaginal prolapse. It is easy to understand, may be easily administered and 
self-completed by the women.
130131132 In view of these attributes this 
questionnaire was chosen to measure the differences in quality of life prior and 
post three months after Vagifem application.  
 
For other studies, Digesu et al examined women who presented with symptoms 
specific to pelvic organ prolapse. It was found that women who had significant 
symptoms also presented greater degrees of pelvic relaxation than women who 
presented without symptoms. Prolapse severity and quality of life scores were 
significantly different in those women symptomatic of prolapse. There was a 
stronger relationship between posterior prolapse and bowel symptoms than 
anterior prolapse and urinary symptoms. Sexual dysfunction was related to 
cervical descent.
133 
 
Fritel et al established that pelvic organ prolapse symptoms were associated with 
difficulty defecating, lower abdominal pain, and difficulty voiding. The frequency 
of POP symptoms was associated with a poorer quality-of-life score in the 
categories physical mobility, pain, emotional reaction, social isolation, energy, 
and sleep. In women above 50 years of age, POP symptoms are associated with 
impaired quality of life, and the number of vaginal deliveries is a risk factor for 
past or present symptomatic POP.
134  81 
 
 
Oestrogen would be given to improve prolapse symptoms and reduce the 
chances of the prolapse worsening, but ultimately long term assessment of pelvic 
floor protein alterations has to be measured in terms of improvements in quality 
of life.  
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1.11  Hypotheses and Objectives 
 
The prevalence of stress incontinence (SI) in white women is much higher (61%) 
than in black African women (27%) and it has been suggested that the elasticity 
of vaginal skin is higher in black women and this could be the reason why black 
women are more protected against SI. Our research group and others have 
demonstrated changes in the collagen I:III ratios in the extracellular matrix of 
vaginal tissue in women with SI compared with controls. As the collagen III 
increases in respect to collagen I the tissue becomes more elastic. Our research 
group has also shown that collagen I and III ratios are different in continent black 
women compared to white and that the collagen III in respect to collagen I is 
higher.
135,
136 In addition it was found that the expression of collagen XVII, a 
collagen with adhesive properties was increased in black women compared with 
white. The above findings suggest better elasticity and adhesiveness in the tissue 
of black women. Thus, it is of interest, if an extracellular component with greater 
elastic characteristics such as elastin is also different in black women and 
changes in SI and pelvic organ prolapse (POP).  
 
The mechanism of POP is poorly understood but it has been proposed that 
oestrogen might alleviate or improve some POP symptoms and or may influence 
surgical outcome. However, previous studies have not been conclusive in 
showing improvements in pelvic organ disorders, although oestrogen has been 
shown to increase pro-mmp2 and new collagen formation in stress incontinent 
women.
137 Although this latter study indicates a positive effect of oestrogen on 
vaginal tissue the use of other oestrogenic compounds has indicated a negative 
influence on POP; for use of raloxifene or levormeloxifene, selective oestrogen 
receptor modulators (SERM), acting partially as inducers or inhibitors of 
oestrogen receptor action, can result in symptomatic prolapse 
138,
139 Therefore, 83 
 
there is interest in future studies that shed light on how oestrogen action can play 
a part in alleviating pelvic organ prolapse conditions. 
 
  
Hypotheses 
It was hypothesised that: 
a)  there is a greater elastin content in black continent women’s vaginal skin 
compared with white women 
b)  stress incontinent women have differing elastin content compared with 
continent controls 
 
Through findings from studies related to above hypotheses it was further 
hypothesised that changes in the vaginal tissue of white women with POP could 
be initiated through the influence of topical, vaginal use of oestrogen: 
 
These hypotheses are therefore : 
1)  Topical oestrogen will increase vaginal skin elasticity in white women with 
POP through 
  a) increasing elastin mRNA expression and protein content 
  b) lowering the collagen I:III ratio, as collagen III has more     
       elastic properties 
 
2)  Topical oestrogen will  
  a) increase MMP2 expression to remodel tissue and      
       reduce stress,  
  b) alter adhesive nature of the tissue for remodelling by      
       altering collagen XVII expression,  
  c) increase ER alpha expression to augment action 84 
 
Objectives  
 
1) The aim is to examine the elastin content of white and black women with or 
without stress incontinence. Periurethral vaginal tissue will be collected, 
processed and analysed by histochemistry. 
 
2) To confirm the hypothesis of improving vaginal tissue characteristics with local 
oestrogen, the following study was designed: 
Women with POP will be recruited, specimens will be taken and clinical 
symptoms recorded pre-treatment and after three months treatment with 
Vagifem®, 25μg 17-β-Oestradiol. Periurethral non stretched tissue will be 
obtained and examined.  
The mRNA expression of MMP2, elastin, ER alpha and collagen XVII as well as 
the protein content of elastin and collagen I and III of vaginal skin will be 
assessed before and after topical oestrogen treatment. 
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Chapter 2 :   
Study Design 86 
 
 
2.1  Ethical approval and Data Protection 
 
Ethical approval for the racial study was obtained by the Tygerberg Hospital 
Ethical Committee in Cape Town, South Africa, project number 2003/033. The 
ethical approval for the prolapse study was granted by the Southampton & South 
West Hampshire Local Research Ethics Committees, REC number 031/04/t 
 
All patient’s files were stored securely in the Urogynaecology Department, 
Princess Anne Hospital, University of Southampton, so that the patient’s private 
data were protected at all time. 
 
 
2.2 Racial  Study 
 
2.2.1 Study  Population 
 
Patients for the racial study were recruited form the gynaecology clinic at 
Tygerberg Hospital in Cape Town. Women awaiting surgery for stress 
incontinence and women awaiting other gynaecological procedures for benign 
conditions not suffering from stress incontinence were recruited given that they 
fulfilled inclusion and exclusion criteria. 87 
 
 
2.2.2  Patient Recruitment, Inclusion and Exclusion Criteria 
 
A detailed history was obtained of each patient recruited for the study including 
past obstetric history, gynaecological, medical and surgical history, as well as 
medication and allergies. Urinary symptoms were recorded. 
 
Inclusion criteria  
    -  age between 18-85 years 
    -  white or black African ethnic group 
    -  awaiting surgery for either stress incontinence 
       or for other benign gynaecological conditions 
    -  urodynamically proven stress urinary incontinence 
    -  able to give written consent 
 
Exclusion criteria 
    -  no proven stress incontinence 
    -  previous history of pelvic floor surgery 
    -  history of irradiation 
    -  medication including 
   -    Diuretics 
      -   ACE inhibitors 
      -  HIV or hepatitis B positive 
    -  medical history including 
      -  chronic cough or constipation 
      -  connective tissue disorders 
   -    diabetes 
      -  haemorrhoids or varicose veins 88 
 
      -  urinary tract infection 
      -  CNS disorders or spinal cord injuries 
      -  genitourinary anomalies or congenital disorders 
   -     P I D  
   -    malignancy 
   -    ligament  injury 
 
 
2.2.3 Patient  Data 
 
An abdominal and vaginal examination was performed to exclude pelvic 
abnormalities or prolapse and to assess vaginal tissue. The perineum was 
assessed and was classified as healthy, scarred or deficient. A cough test was 
performed to exclude stress incontinence symptoms. Routine blood test to 
exclude HIV or Hepatitis B infection was carried out. Women with urinary stress 
incontinence underwent urodynamic studies according to ICS guidelines. These 
included uroflowmetry to measure flow rate and reveal any underlying outflow 
obstruction and cystometry to assess intra vesical pressure and volume during 
bladder filling and voiding. If detrusor instability was demonstrated or urodynamic 
stress incontinence not demonstrated, women were taken out of the study. 
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2.2.4  Obtaining Tissue and Storage 
 
Periurethral full thickness vaginal wall samples were obtained during surgery. A 
10x10mm
2 biopsy was taken and divided into three sections. Two samples were 
fast frozen in liquid nitrogen and stored using the laboratory facilities at -80º C 
until their transport to the UK. The third sample was embedded in paraffin. 
 
During transport to the UK it was ensured that the frozen samples were 
prevented from thawing with the use of dry ice. Regular controls were instigated 
and dry ice added if necessary. 
 
All samples were encoded meticulously and in accordance to the patient 
questionnaire. The details of the patients matching the samples were not 
revealed to the investigator. 
 
 
2.3 Prolapse  Study 
 
The patients for the prolapse study were recruited from the waiting list for an 
anterior and or posterior repair at the Princess Anne Hospital, University of 
Southampton. The women were informed in detail about the study and asked if 
they would give consent to participate. Women who fulfilled the inclusion and 
exclusion criteria and consented were recruited and filled in a data collection and 
symptom questionnaire particularly designed for the study and a Kings Health 
quality of life questionnaire. 
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2.3.1   Patient Recruitment 
 
Women were only recruited for the prolapse study if they fulfilled inclusion and 
exclusion criteria.  
 
Inclusion criteria 
    postmenopausal for at least two years 
    awaiting surgery for at least a stage 2 POP 
 
Exclusion criteria 
    previous vaginal surgery at the planned operation site 
    history of malignancy   
  collagen  diseases   
  stress  incontinence 
 
Women with these conditions were excluded as it is known that these 
predispositions could alter extracellular matrix component expression and 
turnover. 
 
The study was designed initially as a randomised, double blind, placebo 
controlled study. The supplier of the Vagifem tablets initially produced the 
placebos accordingly but unfortunately the packs were inappropriate. As re-
production was not an option for the company the placebo tablets had to be 
removed. The women receiving Vagifem in the present study are therefore acting 
as their own controls as pre-treatment samples and post-treatment samples were 
obtained and subsequently results compared. This design was considered 
appropriate in view of a previous study conducted by Jackson et al in 2002. In 
this study oestradiol valerate was compared to placebo to establish its influence 91 
 
on vaginal tissue in postmenopausal stress incontinence women. Whilst 
synthesis of new collagen and production of pro-MMP2 was found after 6 months 
in the oestrogen treated women the placebo controls showed no significant 
effect
140. 
 
In the present study, patients were asked to fill in a Kings Health Quality of Life 
(QoL) questionnaire and a Standardised Symptoms questionnaire. A detailed 
history including, age, weight, smoking and drinking habits, previous obstetric, 
surgical and medical history was obtained as well as a detailed gynaecological 
and urogynaecological history if present. Allergies and current medication were 
noted accordingly. The symptom sheet can be found in the appendix. A thorough 
abdominal examination was performed together with a vaginal and bimanual 
assessment, in addition to inspection with a Sims speculum. The assessment of 
the stage of prolapse was completed in accordance with the ICS standard (POP-
Q score). A cough test was performed to rule out stress incontinence symptoms. 
 
 
2.3.2  Obtaining and Storage of Tissue 
 
Over the study period it was possible to recruit and see 16 women before and 
after treatment. The study group received a pelvic ultrasound scan to measure 
endometrial thickness and started treatment with topical vaginal oestrogens 
(25μg of 17-β-oestradiol pessaries once daily for 14 days and then 25μg twice 
weekly as recommended by the BNF). 
 
Prior to oestrogen treatment a small full thickness biopsy (5mm x 5mm) from non-
stretched vaginal skin of the vaginal wall involved in the prolapse was obtained 
under local anaesthetic from the patients in the study group. The tissue was 92 
 
obtained using a scalpel to achieve even samples of good size. It is emphasised 
that the tissue was not stretched but was comprised in the prolapse as previous 
studies showed that protein activity and remodelling was significantly higher in 
non-stretched vaginal wall tissue compared to stretched vaginal wall tissue as 
Laborda et al demonstrated.
36  
 
The obtained tissue was washed quickly to remove blood components in 
Dulbecco’s phosphate buffered saline (PBS) PBS 1X with Ca & Mg, Catalog No. 
9236 with a pH of 7.4, containing the following components: 
 
 Dulbecco’s  PBS:       (mg/L) 
- Potassium Chloride (KCl)          200  
- Potassium Phosphate   monobasic (KH2 PO4)    200  
-  Sodium  Chloride  (NaCl)      8000 
- Sodium Phosphate, dibasic (Na2 HPO4)    1150 
- Magnesium Chloride 6H2O (MgCl2 6H2O)    100 
-  Calcium  Chloride  (CaCl)      100   
 
The tissue was then divided into two pieces at approximately a 2:1 ratio. The 
larger piece was frozen rapidly in liquid nitrogen and transferred to the laboratory 
and stored at -80ºC until it was processed. The smaller piece was soaked in 
standardised 10% neutral buffered formalin solution for 24 to 48 hours, then 
transferred into 75% ethanol and transferred to the histopathology laboratory 
where the sample was embedded in paraffin blocks for cutting and staining. The 
same procedure was performed with the samples harvested during surgery. All 
samples were labelled clearly with the initials of the patient, date of birth, study 
number and collection date before storage. 93 
 
 
 
 
 
Chapter 3 :   
Histochemistry 
 94 
 
 
3.1  Histochemistry and Immunocytochemistry 
 
It both studies (racial comparison study and prolapse study) the staining of elastin 
protein was carried out by histochemistry. 
However, for collagen I and III established immunocytochemistry techniques 
were used (prolapse study). 
 
3.2  Fixation and Types of Fixatives 
 
The purpose of fixation is to preserve tissues permanently in as life-like a state as 
possible. Fixation was carried out as soon as possible after removal of the 
tissues to prevent autolysis. Formaldehyde (formalin) was used which forms 
cross links in proteins, especially between lysine residues. These links do not 
change or deteriorate the structure of tissue proteins greatly, so that antigenicity 
is not lost or masked. Formaldehyde is ideal for immunostaining techniques. 
Penetration of the tissue is slow but distinct. The standard solution is 10% neutral 
buffered formalin. A buffer prevents acidity that would promote any autolysis. 
Other fixatives such as glutaraldehyde or mercurials do not penetrate tissue to 
the same degree as formalin or cause deformation of alpha-helix structures in 
proteins and so are not recommended for immunostaining. Both alcohols 
methanol and ethanol cause denaturation of proteins and so are not used for the 
fixation stage but washing in later processes. 
 
Fixation should occur at a neutral pH (6-8) to prevent excessive acidity. Common 
buffers are phosphate, bicarbonate, cacodylate, and veronal. Formalin is buffered 
with phosphate at a pH of 7. There should be a 10:1 volume ratio of fixative to 95 
 
tissue and increasing the temperature enhances the fixation process. Tissues for 
the prolapse study were left in phosphate buffered formalin at room temperature 
for 24 hrs.  
 
Once fixation has taken place the tissue is processed into thin microscopic 
sections. Paraffin was used as a carrier. Paraffin is similar in density to tissue and 
can be cut into slices as thin as 3 micrometers. Tissue was dehydrated to be 
embedded in paraffin. Water was removed by dehydrating the tissue through 
graded alcohol in varying concentrations. (70% to 95% to 100%). Afterwards the 
tissue was “cleared” to remove the insoluble alcohol. Usually xylene, chloroform 
or clearene (aliphatic hydrocarbons) are used. In a final step the tissue was 
immersed in liquid paraffin. The "embedding" process should ensure that the 
tissues are aligned in the right orientation for cutting of the paraffin block and 
preparing the microscopy slides. 
 
 
3.3 Cutting  or  Sectioning 
 
Cutting was performed with a microtome steel blade set to a standard of 4μm 
advance. The sections were floated on warm water to eliminate possible creases. 
They were then picked up onto glass microscopic slides which were coated with 
aminopropyltriethoxysilane (APES). This adhesive provides stability and avoids 
movement of the tissue section during further processing. The slides were stored 
over night at 37°C and then left at room temperature. All slides were labelled 
accordingly similar to the sample cryo tubes. 96 
 
 
3.4  Immunocytochemistry Methods for Collagen I and Collagen III 
3.4.1 Immunoperoxidase  Staining 
 
An antibody reaction was used to detect specific protein (Collagen I and collagen 
III). These antibodies can be monoclonal or polyclonal. (Monoclonal antibodies 
derive from cell cultures and often only bind to one protein epitope. Polyclonal 
antibodies are obtained from animals and so form a heterogeneous blend of 
antibodies able to detect a variety of protein epitopes.) Direct or indirect probing 
can be performed using one or two types of antibodies. The latter is called the 
“sandwich” technique and was used in this study. The sandwich technique is 
used to ensure an enhanced reaction compared to a direct antibody staining. In 
the direct method a customised antibody would be required for any variety of 
antigens of interest. 
 
In the Indirect immunoperoxidase staining technique, the specific (primary) 
antibody was bound to the tissue sample and then coupled with a tagged 
secondary antibody carrying small molecules that can be recognised by a 
peroxidase-conjugated binding molecule with high affinity. The most common 
example for this is a biotin linked antibody that binds to an enzyme-bound 
streptavidin. This method can be used to amplify the signal.  
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Figure 3.1 Scheme of peroxidase staining, using primary and secondary 
antibodies 
 
 
Detection is typically performed using the peroxidase linked antibodies. 
Biotinylated secondary antibodies were coupled with peroxidase which reacts 
with 3,3'-diaminobenzidine (DAB) and produces brown staining. The reaction can 
be enhanced using nickel, producing a deep purple/grey staining.
141  The amount 
of colour produced is equivalent to the quantity of enzyme and therefore 
equivalent to the amount of tissue antigen that is to be assessed.  
 
To ensure that only the specific reactions are detected all other innate enzymes 
which could produce similar colour changes needed to be inactivated. Otherwise 
falsification of results would occur. For this 0.5% hydrogen peroxidase in 
methanol was used for ten minutes to ensure inhibition. The tissue was then 
washed three times with Tris buffered saline (TBS) for two minutes. 98 
 
 
3.4.2  Antigen Retrieval  
 
Through formalin fixation and paraffin embedding, antigen sites can be hidden 
and need to be unmasked. For this Heat Induced Epitope Retrieval (HIER) was 
used to break the cross links formed by formalin fixation. This technique involved 
heating the paraffin-embedded tissue for varying lengths of time in an aqueous 
solution. (Retrieval solution). Hidden antigenic sites are recovered and the 
staining reaction is enhanced.  
 
 
3.4.3 Antibodies   
 
Primary antibodies used were - 
1.  for collagen I, a mouse monoclonal from Abcam (Cambridge, UK) 
2.  for collagen III, a rabbit polyclonal from Cedarlane Laboratories, 
 (Canada) 
 
The tissue was incubated with the primary antibodies overnight at 4°C and 
washed three times for 5 minutes in TBS. Biotinylated secondary antibodies were 
used to build a primary-secondary- antibody complex and the slide was incubated 
for 30 minutes. 
 
Secondary antibody used  
3.  for collagen I:   anti-mouse IgG 
4.  for collagen III: anti rabbit IgG 
 
Slides were then washed again three times using TBS. 99 
 
3.4.4  High Affinity Reaction 
 
Streptavidin- Biotin-peroxidase complexes (ABC, by Dakocytomation, Ely,UK) 
were applied  for 30 minutes for a high affinity interaction. Streptavidin is a 
tetrameric 60kD Avidin analogue isolated from Streptomyces avidinii. It has a 
high affinity to biotin (106 times higher compared to normal antibody-antigen 
binding) and is able to bind four biotin molecules simultaneously. The biotin is 
conjugated to the peroxidase enzyme. Thus it amplifies the antibody-antigen 
complex formation.  
 
The chromogen used in this study was DAB (as described above). It is insoluble 
in alcohol and so achieves permanent, brown staining. It was applied for 5 
minutes and washed with TBS and water. Counter staining was undertaken with 
Mayers haematoxylin blue dye. The slides were dehydrated with graded 
concentrations of alcohol, washed with xylene (phenol solvent) and mounted in 
Di-n-butyl Phthalate (DPX). Subsequently they were left at room temperature for 
analysis. 
 
 
3.5 Elastin 
 
Imaging of elastin fibres in vaginal tissue does not necessarily require an 
antibody binding process as does collagen imaging. Staining with elastic van 
Gieson (EVG) method was performed for samples of the stress incontinence and 
the prolapse study.  
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Samples were embedded in paraffin and 4μm sections cut and floated on warm 
water. They were then floated onto glass slides, coated with 
aminopropyltriethoxysilane (APES) providing an adhesive for the tissue to obtain 
the histological correctness and dried overnight at 37°C. 
 
The elastic fibres were then stained by the Elastic van Gieson method. Sections 
were dewaxed in Clearene, and rehydrated through decreasing concentrations of 
alcohol to water and then treated in 0.5% Potassium permanganate for 5 
minutes. They were then rinsed in distilled water and bleached in 1% Oxalic acid 
for 3 minutes, rinsed in distilled water and then in 95% alcohol. They were then 
stained with Millers Elastin Stain for 3 hours. (A combination of Victoria Blue, 
New Fuchsin, Crystal Violet, Resorcinol, Dextrin and Ferric chloride. Excess stain 
was removed with 95% alcohol, and the sections washed in running water for 2 
minutes. The nuclei were then stained with Weigert's iron haematoxylin (1% 
alcoholic haematoxylin in acidified ferric chloride) for 5 minutes. They were then 
washed in running tap water to "blue" the nuclei, and then counterstained with 
Van Gieson stain for 5 minutes (10 ml 1% aqueous acid fuchsin + 100ml 
saturated aqueous picric acid. The sections were then dehydrated through 
increasing grades of alchohol, "cleared" in clearene and mounted in a synthetic 
mounting medium (eg DPX, pertex, etc.) 
Elastic fibres are presented blue/black, cell nuclei black, muscle tissue yellow, 
and connective tissue red. 
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Figure 3.2 Elastin fibres in Elastic van Gieson staining. The fibres appear black 
meanwhile collagen fibres are red stained. (Amplification x40). 
 
 
Figure 3.3 Elastin Fibres in Elastic van Gieson Staining in another sample. Less 
fibres are present (Amplification x40). 
blood vessel 
elastin fibres 
elastin fibres 
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Figure 3.4 Elastic van Gieson Staining in a sample with a high percentage of 
elastin fibres. (black), (Amplification x40) 
 
An image analysis system by Zeiss was used to analyse the microscopic slides 
for collagen I, III and elastin. (Zeiss KS400 software, Image Associates, Bicester, 
UK). The system includes a microscope (Zeiss Axioskope 2 MOT) with an 
attached camera (Zeiss Axiocam) and connection to a computer with the required 
program to analyse the measured data (KS400.30 from Image Associates). Each 
slide was assessed to ensure morphological correctness and the different layers 
of vaginal skin were identified prior to measurement. Three to five sections of 
each slide were randomly chosen and areas of artefact or vessels were omitted 
using the computer system before the percentage content of Collagen I or 
Collagen III was assessed based on the red, green, blue colour composition. The 
average of each of the three sections was calculated and taken as overall 
percentage content for that particular slide.  
elastin fibres 
elastin fibres 103 
 
Collagen ratio was then calculated by dividing the percentage of collagen I 
content by the percentage collagen III content. 
 
  Collagen  I  (%) 
                                 = Ratio collagen I/III 
  Collagen  III  (%) 
 
The percentage elastin content (grey/black staining) was measured alike using 
the above mentioned computer-assisted image analysis based on its red-green-
blue colour balance. Reproducibility was assured by repeatedly measuring the 
same areas in a number of slides and calculating the coefficient variation of the 
results which varied between 7 and 10%.  
 
          standard deviation of the mean 
          CV %  =            X 100 
            m e a n  104 
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4.1  Techniques for Homogenizing Tissue Samples for Real Time PCR 
 
The tissues of the racial and the prolapse study were processed in the same way. 
The techniques therefore apply for both studies. 
 
 
4.1.1  Cutting of the Samples 
 
The samples were removed from the -80º C freezer and stored immediately on 
dry ice. The samples were cut in a sterile plastic petri dish to prevent 
contamination and on dry ice to prevent thawing. All other instruments used 
(forceps, blade, spatula, sample container) were sterile and cooled on dry ice. 
Afterwards, samples were weighed using a calibrated, sensitive sheltered 
balance and the sample weights were approximately 50mg. 
 
The samples were kept individually in labelled cryo tubes on dry ice and were 
then homogenized using 500μl of TRIzol® as recommended by “Invitrogen life 
technologies” instructions for the use of Trizol. TRIzol® is a mono-phasic solution 
of phenol and guanidine isothiocyanate and is used for the isolation of total RNA 
from cells and tissues. It maintains the integrity of the RNA while disrupting cells 
and dissolving cell components. It has the advantage to have a broad spectrum 
of efficacy and can be used for tissue quantities from a few mg up to 1g. It can be 
used for isolation of a variety of RNA species of large or small molecular size. 
The isolated RNA has an A260/A280 ratio of ≥1.8 when diluted into TE buffer.
142 
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4.1.2 Homogenization  Techniques 
 
After grinding the tissue to powder in a pulveriser cooled by liquid nitrogen, the 
tissue powder was retrieved with a sterile spatula and transferred instantly into 
500μl TRIzol® and was then homogenized. Homogenization was performed with 
a Labour technik T8.01 Ultra-Turrax homogenizer by IKA Werke GmbH & co.KG, 
Staufen, Germany, using 15 sec bursts on ice so that the tissue did not overheat. 
 
All metal parts were thoroughly cleaned between samples with water and 100% 
Ethanol to stop cross over contamination and cooled again to prevent thawing. 
Comparative trials using only the Ultra-Turrax homogenizer, and both the grinder 
and homogenizer in combination showed that the RNA concentration was 
considerably higher in the sample that was ground and homogenized. 
 
Example – 
Sample  A260  A280  A260/280  RNA Concentration  
1 
homogenized 
AND ground 
 
0.067 
 
0.048 
 
1.895 
 
0.67μg/μl 
2 
homogenized 
only 
 
0.034 
 
0.026 
 
1.813 
 
0.34 μg/μl 
Table 4.1 Calculation for RNA quantification and the method of spectro-
photometry follows later. 
 
 107 
 
4.1.3  RNA Extraction and Quantification of RNA 
 
Once the tissue was ground and homogenised it was left in the TRIzol® reagent 
to incubate for 30 min at room temperature to permit the complete dissociation of 
nucleoprotein complexes. 
  
The following steps were then used for RNA extraction using TRIzol® reagent: 
 
1) 100μl of Chloroform were added (200μl per 1ml of TRIzol®)  
2)   Mixture shaken thoroughly for 15 sec 
3)   Incubated at room temperature for 5 min 
4)   Centrifuged at 12.000rpm for 10 min 
 
Following centrifugation the mixture separated into a lower, red phenol-
chloroform phase, a white interphase and a clear upper aqueous phase. 
 
5)  the top layer was transferred (supernatant aqueous phase) to a  
    clean, labelled tube, ensuring that only the clear top layer was  
    used and the other, lower layers remained undisturbed as this  
    would have contaminated the RNA-rich supernatant. 
6)   20μl of Glycogen (concentration 2mg/ml) was added to aid  
     precipitation 
7)   250μl of isopropylalcohol was then added (500μl per 1 ml of  
   TRIzol®) 
8)   It was left on ice for 10 min 
9)   Precipitate was centrifuged down for 10 min at 12.000rpm 
10)   Supernatant was removed carefully to leave small pellet of  
    glycogen and RNA  
11)   Pellet was washed with 500μl of 75% ethanol 108 
 
12)   After mixing the precipitate was centrifuged down at 12.000rpm  
    for 10 min 
13)   Ethanol was then removed and pellet allowed to dry 
14)   The RNA was dissolved in 20μl of ultra pure water 
15)   The RNA concentration was measured in a spectrophotometer  
    and quality also assessed by Agarose gel electrophoresis to  
    assess 18s and 28s ribosomal bands. 
 
 
4.1.4  Quantification of RNA 
 
A Jenway 6505 UV/vis (UK) spectrophotometer was used  
 
 
Figure 4.1 Jenway 6505 UV/visuel (UK) Spectrophotometer. 
 
It is a single beam spectrophotometer having a 1.8nm bandpass and offering 
spectrum scanning, quantitation, kinetics and multi-wavelength measurements. It 
operates between 190-1100nm. 
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RNA absorbs light mainly at 260nm whereas protein absorbs light at 280nm, but 
RNA absorption overlaps into the 280nm band. These characteristics are used to 
quantify RNA content in a sample in relation to protein content (A260/A280). If 
there is over 95% RNA content with little protein contamination then the ratio 
should be between 1.5 and 2. Lower ratios would mean that the sample is 
contaminated and not valid for further usage. 
 
To test a sample 2μl were taken initially and used for spectrophotometry. If 
readings were too low then 10μl of extracted RNA were used and diluted with 
500μl of purified water in the instrument’s cuvettes. After mixing, the cuvette was 
placed in the spectrophotometer and measured using the multiwavelength 
setting. 
 
RNA concentration was calculated using the principle that if A260 is equal to 1, 
through a 1cm path (thickness of the cuvette), then the concentration is 
equivalent to 40μg RNA per ml. 
 
Table 4.2 Calculation scheme for RNA concentration 
 
Cuvette volume  500 ul       
RNA soln.  volume  2  ul       
Abs A260  0.104  so  RNA  4.16  ug/ml  in 
cuvette 
cuvette total  RNA  2.08  ug       
therefore RNA 
conc 
1.04 ug/ul  ***     
vol. orig  RNA 
soln. 
20 ul       
total RNA  orig. soln.  20.8  ug       110 
 
The example above refers to a sample of 2μl RNA in 500μl water with A260 as 
0.104nm giving a concentration of 4.16μg/ml  
(0.104 x 40μg/ml = 4.16μg/ml, i.e. 2.06μg in 2μl diluted in 500μl water in cuvette). 
 
 
4.1.5  Dilution of RNA 
 
The samples used for a PCR assay contained similar concentrations before they 
were processed in further steps to ensure valid and comparable data. The assays 
were optimised so that expression of a particular gene fell within the range of the 
assay. The RNA was diluted to an approximate concentration of 0.5 ug/μl. 
 
 
4.1.6  Agarose Gel  
 
The purity of RNA is tested using Agarose gels before cDNA is made. The RNA 
for 18s and 28s is looked for to assess the quality. 
 
Details for the gel electrophoresis: 
500mg agarose was dissolved in 50 ml of 1 x TAE buffer by heating in a 
microwave oven to produce a 1% solution. While still in solution 1.5μl of ethidium 
bromide solution (10mg/ml) was mixed into the agarose solution, which was then 
poured into a gel holder and a comb placed in the gel before allowing to set at 
room temperature  111 
 
RNA samples were made up in the following mixture before loading into the gel: 
2μl of RNA solution 
2μl deionised formamide 
1μl Northern loading buffer 
5μl RNAse free water 
 
Samples were then run in the gel at a voltage of 10volts/cm across the gel for 30 
min. The gel was then visualized under a UV light and a photograph taken of the 
gel. 
 
Figure 4.2: Intact versus degradred RNA. Two μg of degraded total RNA and 
intact total RNA were run beside Ambion’s RNA Millenium Markers on a 1,5% 
denaturating Agarose gel. The 18S and 28S ribosomal RNA bands are clearly 
visible in the intact RNa sample. The degraded RNA appears as a lower 
molecular weight smear 
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Figure 4.3: Typical picture of agarose gel with intact and clear RNA samples 
 
 
4.1.7 Reverse  transcription 
 
To quantify the expression of a gene by PCR the RNA had to be reverse 
transcribed into complementary DNA (cDNA) and then the region of interest was 
amplified using PCR. Reverse transcription followed by PCR was used in 
preference to Northern blot analysis or RNAse protection assay, as RT-PCR is 
able to quantify much smaller amounts of RNA. 113 
 
 
Figure 4.4 Reverse Transcription Process Diagram 
 
Reverse transcription was performed using M-MLV transcriptase (200U/μl) from 
Promega, Southampton (Code M1701). Moloney Murine Leukemia Virus Reverse 
Transcriptase (M-MLV RT) is an RNA-dependent DNA polymerase that can be 
used in cDNA synthesis with long messenger RNA templates (>5kb). It is 
preferred because the RNase H activity of M-MLV RT is weaker than the 
commonly used Avian Myeloblastosis Virus (AMV) reverse transcriptase.
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M-MLV Reverse Transcriptase is supplied in 20mM Tris-HCl (pH 7.5), 200mM 
NaCl, 0.1mM EDTA, 1mM DTT, 0.01% Nonidet® P-40 and 50% glycerol. M-MLV 
RT 5X Reaction Buffer is diluted 1:5 and contains the following: 
  250mM Tris-HCl (pH 8.3 at 25°C) 
 375mM  KCl 
 15mM  MgCl2 
 50mM  DTT 114 
 
M-MLV Reverse Transcriptase is less active than AMV Reverse Transcriptase, 
and therefore, more units (1 unit is defined as the amount of enzyme required to 
catalyze the transfer of 1nmol of deoxynucleotide into acid-precipitable material in 
10 minutes at 37°C) of the M-MLV enzyme are required to generate the same 
amount of cDNA as in the AMV reaction. Starting with 1μg of mRNA in a first-
strand cDNA synthesis, 200 units of the M-MLV enzyme were used. 
 
The following procedure used 2μl (1μg) of RNA. Initially random primers 
(500ng/μl) were diluted with ultrapure water in a ratio of 0.8μl:12.2μl and 2μl of 
RNA are added giving a total volume of 15μl per sample of RNA. A sterile 
RNase-free microcentrifuge tube was used for this. The mixture was heated at 
70ºC for 5 minutes to open up secondary structure within the template and then 
cooled on ice for the random primers to anneal to the template. This was mixture 
1. In the meantime further RT reagents were mixed (amounts below were for 1 
sample and needed to be multiplied according to the sample number=n used.) 
 
 1)  RT  buffer      5μl  
2) dNTPs (PCR mix 10mM)      1.25μl 
    containing 
  dATP, 10mM   
  dCTP, 10mM  
  dGTP, 10mM  
 dTTP,  10mM   
3) recombinant RNasin®  
    Ribonuclease Inhibitor (40U/μl) -  0.625μl 
4) M-MLV transcriptase (200U/μl) -  1.0μl   
5) ultra pure water      -  2.125μl 
Making a total volume of:      10μl 115 
 
 
This second mixture was mixed gently and added to mixture 1 after the cooling 
stage, then mixed again and centrifuged.  
 
A preset program for the reverse transcription reaction was run on a Hybaid 
thermal reactor as follows: 
  1 hour at 37°C 
  10 minutes at 42°C 
  10 minutes at 75°C (to denature enzyme and stop reaction)
144,
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4.1.8   Polymerase Chain Reaction (PCR) 
 
The mRNA expression of oestrogen receptor α, MMP2, elastin and collagen XVII 
in the prolapse study were measured using real time PCR. The technique was 
similar for each of the genes but primer optimisation was performed prior to 
testing. The different measurements are described separately to signify the 
regions of interest and the primers and probes used. 
 
The basic principle of the polymerase chain reaction for mRNA expression is to 
amplify cDNA representing the mRNA of interest and not genomic DNA that can 
contain both exons (parts of the gene coding for the mRNA and thus protein) and 
introns (areas between exons with no coding message). As introns are spliced 
out in the production of mRNA, primers can be designed to go over exon-exon 
junctions so that any contaminating DNA will not be amplified. The PCR amplifies 
a specific sequence representing the mRNA of interest. mRNA sequences were 
obtained from the National Center for Biotechnology Information (NCBI) website 
http://www.ncbi.nlm.nih.gov/ 116 
 
 
The primers and probes were designed using the Applied Biosystems software 
Primer Express. As DNA is made of two complementary strands, a forward and 
reverse primer are necessary to read in either direction: from 5’ end to 3’ end of 
each DNA strand. For this the DNA strands is separated, a process called 
denaturation requiring high temperatures at around 95°C to take place. The 
temperature is lowered for the primer to bind and complement one of the DNA 
strands, a process referred to as annealing. Taq polymerase, an enzyme that 
catalyzes the polymerization of deoxyribonucleotides into a DNA strand, builds 
the complementary DNA strand using deoxynucleoside triphosphates (dNTPs) 
from the annealed primer (at the same temperature or raised to 72ºC). This step 
is called extension step. 
 
The PCR usually consists of a series of 20 to 40 repeated temperature changes 
(or cycles) to increase the amount of DNA produced exponentially. The 
temperatures used and the length of time they are operated in each cycle depend 
on the enzyme used for DNA synthesis, the concentration of divalent ions and 
dNTPs in the reaction, and the melting temperature of the primers.
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Temperatures recommended for the different steps are: 
 
Denaturation step  
The DNA is heated 94-98°C for 20-30 seconds. This starts the melting of the 
DNA template and primers by disrupting the hydrogen bonds. 
 
Annealing step 
The reaction temperature is 50-65°C for 20-40 seconds allowing annealing of the 
primers to the single-stranded DNA template. The polymerase binds to the 
primer-template complex and starts the DNA synthesis. 117 
 
Elongation step 
The polymerase used for this step determines the temperature. The new 
complementary DNA to the template is built by adding dNTPs. The velocity of the 
elongation depends again on the polymerase used and the length of the DNA 
sequence being amplified. For real-time PCR, polymerases have been produced 
that can work at 60ºC and therefore annealing and extension are carried out at 
this temperature. The PCR reaction is then made much faster. The primers and 
probes are designed appropriately to work at this temperatue of 60ºC. 
 
Cooling step (final hold) 
The cycles can be stopped and the DNA preserved at 4-15°C for short-term 
storage of the reaction. 
 
 
Figure 4.5 Schematic Drawing of a typical PCR Cycle. 
Step 1: Denaturing at 94-96°C S 
Step 2: Annealing at ~65°C 
Step 3: Elongation at 72°C for several Cycles 118 
 
For the real-time cycle – After denaturation, both annealing and extension occurs 
at 60ºC and therefore there are only 2 steps. In all of the following tests real time 
PCR was used. Real time PCR is also known as “quantitative real time 
polymerase chain reaction (Q-PCR)” or “kinetic polymerase chain reaction”. It 
provides the possibility of detection and quantification of a specific sequence of 
DNA in a sample.  
 
The main difference to endpoint PCR is that the amplified DNA can be quantified 
in real time in the exponential phase of DNA amplification. Fluorescent DNA 
oligonucleotide probes with a quencher at one end are used that hybridise with 
the complementary DNA in the areas of interest between the primer areas. As the 
polymerase copies a DNA strand it digests the probe and releases the quencher 
from the fluorescent dye, whose fluorescent signal is then recorded. This 
fluorescent signal is proportional to the amount of DNA being produced. The 
probe contains a high energy dye, called a “Reporter” at the 5’ end, (often 6-
carbofluorescein is used) and a low energy “Quencher” at the 3’ end (6-carboxy-
tetramethyl-rhodamine). The quencher prevents fluorescence from being 
produced as long as the probe is intact.  119 
 
 
Figure 4.6 Cycle Threshold (Ct)(green line) for cycle measurement for 
fluorescence for standard and controls of assay for MMP2 in prolapse study 
 
During the reaction the change in fluorescence is plotted against the cycle 
number on a semi-logarithmic scale (Figure 4.6). A threshold for detection of 
fluorescence above background is determined. The cycle at which the 
fluorescence from a sample crosses the threshold is called the cycle threshold 
(Ct). A standard curve with known amounts of starting DNA (or mRNA) or 
dilutions of mRNA (arbitrary amount) can then be constructed from Ct values and 
known amounts of DNA. On a semi logarithmic graph this gives a straight line 
(see Figure 4.7) 
 
 120 
 
 
Figure 4.7 Logarithmic Graph of Standard Curve for MMP2 RNA 
 
Unknown amounts of mRNA or DNA are then determined by reading the results 
off of the standard curve. The real-time systems used were the Applied 
Biosystems 7700 and later the 7500 with the ABI Prism Sequence Detection 
System software. 
 
The results were calculated in relation to the expression of an internal control or 
housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH or 
G3PDH). GAPDH is an enzyme that catalyses the sixth step of glycolysis and 
thus serves to breakdown glucose.  This gene belongs to the group of standard 
housekeeping genes. The RNA of housekeeping genes are produced regularly to 
maintain cell function continually and thus are generally unaltered dramatically 
when external stimuli change. Therefore when expression of genes of interest 
change, it is more accurate to measure them relative to this internal control that 121 
 
has been taken through all the molecular biology techniques. Dividing the 
calculated mRNA amount for gene of interest by the amount of RNA from the 
house keeping gene measured in the same sample normalises the results for 
possible variation in the amount and quality of RNA between different samples. 
This normalisation ensures that the expression of the gene of interest can be 
accurately compared between different samples given that the expression of the 
housekeeping gene used in the normalisation is similar for all the samples. It is 
essential to use a housekeeping gene that is fulfilling this criterion. 
 
 
4.1.9  Elastin Genome, Primer and Probe 
 
Elastin mRNA expression was measured for both studies, Racial differences in 
stress incontinence and oestrogen influence on prolapsed vaginal tissue. The 
elastin gene can be found in the proximal region of the long arm of chromosome 
7.
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The primers and probe were designed using primer express with the mRNA 
sequence for elastin, Accesion number NM_000501, and designed to pick up a 
common part of all alternatively spliced elastin forms. These were designated h-
eln-f, h-eln-r and h-eln-p 122 
 
The gene sequences were written from 5’ to 3’ 
Forward primer h-eln-f: 
   CCA-GGT-GTA-GGT-CGA-GCT-TTT-G 
Reverse primer h-eln-r: 
   CCC-AGT-GGG-ACT-CCA-GGT-T 
Probe h-eln-p: 
   CAA-AGG-GTC-CAA-CTC-CTG-GGA-TTC-CA 
and manufactured by EUROGENTEC, Belgium: www.eurogentec.com 123 
 
Homo Sapiens Elastin Gene Nucleotide Sequence 
ORIGIN 
1    gcgggctggg gcatttctcc ccgagatggc gggtctgacg gcggcggccc cgcggcccgg 
61   agtcctcctg ctcctgctgt ccatcctcca cccctctcgg cctggagggg tccctggggc 
121  cattcctggt ggagttcctg gaggagtctt ttatccagcg ctggggcctg gaggcaaacc 
181  tcttaagcca gttcccggag ggcttgcggg tgctggcctt ggggcagggc tcggcgcctt 
241  ccccgcagtt acctttccgg gggctctggt gcctggtgga gtggctgacg ctgctgcagc 
301  ctataaagct gctaaggctg gcgctgggct tggtggtgtc ccaggagttg gtggcttagg 
361  agtgtctgca ggtgcggtgg ttcctcagcc tggagccgga gtgaagcctg ggaaagtgcc 
421  gggtgtgggg ctgccaggtg tatacccagg tggcgtgctc ccaggagctc ggttccccgg 
481  tgtgggggtg ctccctggag ttcccactgg agcaggagtt aagcccaagg ctccaggtgt 
541  aggtggagct tttgctggaa tcccaggagt tggacccttt gggggaccgc aacctggagt 
601  cccactgggg tatcccatca aggcccccaa gctgcctggt ggctatggac tgccctacac 
661  cacagggaaa ctgccctatg gctatgggcc cggaggagtg gctggtgcag cgggcaaggc 
721  tggttaccca acagggacag gggttggccc ccaggcagca gcagcagcgg cagctaaagc 
781  agcagcaaag ttcggtgctg gagcagccgg agtcctccct ggtgttggag gggctggtgt 
841  tcctggcgtg cctggggcaa ttcctggaat tggaggcatc gcaggcgttg ggactccagc 
901  tgcagctgca gctgcagcag cagccgctaa ggcagccaag tatggagctg ctgcaggctt 
961  agtgcctggt gggccaggct ttggcccggg agtagttggt gtcccaggag ctggcgttcc 
1021 aggtgttggt gtcccaggag ctgggattcc agttgtccca ggtgctggga tcccaggtgc 
1081 tgcggttcca ggggttgtgt caccagaagc agctgctaag gcagctgcaa aggcagccaa 
1141 atacggggcc aggcccggag tcggagttgg aggcattcct acttacgggg ttggagctgg 
1201 gggctttccc ggctttggtg tcggagtcgg aggtatccct ggagtcgcag gtgtccctgg 
1261 tgtcggaggt gttcccggag tcggaggtgt cccgggagtt ggcatttccc ccgaagctca 
1321 ggcagcagct gccgccaagg ctgccaagta cggagtgggg accccagcag ctgcagctgc 
1381 taaagcagcc gccaaagccg cccagtttgg gttagttcct ggtgtcggcg tggctcctgg 
1441 agttggcgtg gctcctggtg tcggtgtggc tcctggagtt ggcttggctc ctggagttgg 
1501 cgtggctcct ggagttggtg tggctcctgg cgttggcgtg gctcccggca ttggccctgg 
1561 tggagttgca gctgcagcaa aatccgctgc caaggtggct gccaaagccc agctccgagc 
1621 tgcagctggg cttggtgctg gcatccctgg acttggagtt ggtgtcggcg tccctggact 
1681 tggagttggt gctggtgttc ctggacttgg agttggtgct ggtgttcctg gcttcggggc 
1741 agtacctgga gccctggctg ccgctaaagc agccaaatat ggagcagcag tgcctggggt 
1801 ccttggaggg ctcggggctc tcggtggagt aggcatccca ggcggtgtgg tgggagccgg 
1861 acccgccgcc gccgctgccg cagccaaagc tgctgccaaa gccgcccagt ttggcctagt 
1921 gggagccgct gggctcggag gactcggagt cggagggctt ggagttccag gtgttggggg 
1981 ccttggaggt atacctccag ctgcagccgc taaagcagct aaatacggtg ctgctggcct 
2041 tggaggtgtc ctagggggtg ccgggcagtt cccacttgga ggagtggcag caagacctgg 
2101 cttcggattg tctcccattt tcccaggtgg ggcctgcctg gggaaagctt gtggccggaa 
2161 gagaaaatga gcttcctagg acccctgact cacgacctca tcaacgttgg tgctactgct 
2221 tggtggagaa tgtaaaccct ttgtaacccc atcccatgcc cctccgactc cccaccccag 
2281 gagggaacgg gcaggccggg cggccttgca gatccacagg gcaaggaaac aagaggggag 
2341 cggccaagtg ccccgaccag gaggccccct acttcagagg caagggccat gtggtcctgg 
2401 ccccccaccc catcccttcc cacctaggag ctccccctcc acacagcctc catctccagg 
2461 ggaacttggt gctacacgct ggtgctctta tcttcctggg gggagggagg agggaagggt 
2521 ggcccctcgg ggaaccccct acctggggct cctctaaaga tggtgcagac acttcctggg 
2581 cagtcccagc tccccctgcc caccaggacc caccgttggc tgccatccag ttggtaccca 
2641 agcacctgaa gcctcaaagc tggattcgct ctagcatccc tcctctcctg ggtccacttg 
2701 gccgtctcct ccccaccgat cgctgttccc cacatctggg gcgcttttgg gttggaaaac 
2761 caccccacac tgggaatagc caccttgccc ttgtagaatc catccgccca tccgtccatt 
2821 catccatcgg tccgtccatc catgtcccca gttgaccgcc cggcaccact agctggctgg 
2881 gtgcacccac catcaacctg gttgacctgt catggccgcc tgtgccctgc ctccaccccc 
2941 atcctacact cccccagggc gtgcggggct gtgcagactg gggtgccagg catctcctcc 
3001 ccacccgggg tgtccccaca tgcagtactg tatacccccc atccctccct cggtccactg 
3061 aacttcagag cagttcccat tcctgccccg cccatctttt tgtgtctcgc tgtgatagat 
3121 caataaatat tttatttttt gtcctgg 
Figure 4.8 Homo sapiens mRNA for Elastin precursor variant protein, Accession 
number: AB208942 Totoki,Y., Toyoda,A., Takeda,T., Sakaki,Y., Tanaka,A., 
Yokoyama,S., Ohara,O., Nagase,T. and Kikuno,R.F. TITLE Homo sapiens 
protein coding cDNA, JOURNAL   Published Only 
(Yellow - forward primer; Green- reverse primer; Red - probe) 124 
 
4.1.10  PCR for Elastin mRNA Expression 
A standard curve was set up initially to ensure pipetting and accuracy of the 
measurement. The sample used (V87) showed RNA concentration of 0.98μg/μl 
(A260: 0.098)  
 
Standard curve dilution was performed as per protocol: 
Step 1) RNA made up to 20ul at a concentration of 0.5μg/μl (S7 standard) 
Step 2) double dilution with 10μl water per sample until S1 
 
            10μl 
 
              S7   S6    S5   S4    S3   S2    S1 
Figure 4.9 Dilution for producing a Standard Curve 
 
Step 3) 3μl taken from S7 diluted with 21μl water for controls (C1 – C6) 
 
Reverse transcription was performed as per protocol using 2μl of RNA from all 
samples including standard and controls and PCR was performed testing 
standards and controls. PCR was repeated with the samples in conjunction with 
the standards and controls. PCR was repeated using the set protocol. 125 
 
Constituents and volumes: 
 3 μl forward primer (10μM) 
 3 μl reverse (10μM) 
 3 μl probe (5μM) 
 50μl universal mix 
Then made up to 100 μl with ultra pure water and cDNA. 
 
All volumes are for sample number, n =1.  With increasing sample number the 
measurements need to be multiplied appropriately. 96μl of the mastemix were 
dispensed for each sample and 4μl of cDNA from each sample added 
correspondingly. The components were vortexed, spun down and 45μl evenly 
distributed in duplicates into wells of a sterile microtitre plate. The assay for 
GAPDH was mixed and dispensed in the same way. The real-time PCR 
programme was then run in the 7700 or 7500 ABI machines. 
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4.1.11  PCR for MMP2 Expression  
 
Reverse transcription and real time PCR were performed similarly to the elastin 
RNA assay for the same samples. Probes from Eurogentec were used.  
 
Sequences written 5’ to 3’. 
Forward primer HMMP2F:   
   GAG-ATC-TGC-AAA-CAG-GAC-ATT-GTA-TT 
Reverse primer HMMP2R: 
   CCA-AAT-GAA-CCG-GTC-CTT-GA 
Probe HMMP2T: 
   CAC-CAC-GGA-TCT-GAG-CGA-TGC-CAT 
 
Dilutions were made for primer and probe with the primer amount of 10μM and of 
the probe 5μM. RT and PCR were performed after making standards and 
controls for n=50 (49 samples + 1). 127 
 
Homo Sapiens MMP2 mRNA Genome 
ORIGIN       
   1 acatctggcg gctgccctcc cttgtttccg ctgcatccag acttcctcag gcggtggctg 
  61 gaggctgcgc atctggggct ttaaacatac aaagggattg ccaggacctg cggcggcggc 
 121 ggcggcggcg ggggctgggg cgcgggggcc ggaccatgag ccgctgagcc gggcaaaccc 
 181 caggccaccg agccagcgga ccctcggagc gcagccctgc gccgcggagc aggctccaac 
 241 caggcggcga ggcggccaca cgcaccgagc cagcgacccc cgggcgacgc gcggggccag 
 301 ggagcgctac gatggaggcg ctaatggccc ggggcgcgct cacgggtccc ctgagggcgc 
 361 tctgtctcct gggctgcctg ctgagccacg ccgccgccgc gccgtcgccc atcatcaagt 
 421 tccccggcga tgtcgccccc aaaacggaca aagagttggc agtgcaatac ctgaacacct 
 481 tctatggctg ccccaaggag agctgcaacc tgtttgtgct gaaggacaca ctaaagaaga 
 541 tgcagaagtt ctttggactg ccccagacag gtgatcttga ccagaatacc atcgagacca 
 601 tgcggaagcc acgctgcggc aacccagatg tggccaacta caacttcttc cctcgcaagc 
 661 ccaagtggga caagaaccag atcacataca ggatcattgg ctacacacct gatctggacc 
 721 cagagacagt ggatgatgcc tttgctcgtg ccttccaagt ctggagcgat gtgaccccac 
 781 tgcggttttc tcgaatccat gatggagagg cagacatcat gatcaacttt ggccgctggg 
 841 agcatggcga tggatacccc tttgacggta aggacggact cctggctcat gccttcgccc 
 901 caggcactgg tgttggggga gactcccatt ttgatgacga tgagctatgg accttgggag 
 961 aaggccaagt ggtccgtgtg aagtatggga acgccgatgg ggagtactgc aagttcccct 
1021 tcttgttcaa tggcaaggag tacaacagct gcactgatac cggccgcagc gatggcttcc 
1081 tctggtgctc caccacctac aactttgaga aggatggcaa gtacggcttc tgtccccatg 
1141 aagccctgtt caccatgggc ggcaacgctg aaggacagcc ctgcaagttt ccattccgct 
1201 tccagggcac atcctatgac agctgcacca ctgagggccg cacggatggc taccgctggt 
1261 gcggcaccac tgaggactac gaccgcgaca agaagtatgg cttctgccct gagaccgcca 
1321 tgtccactgt tggtgggaac tcagaaggtg ccccctgtgt cttccccttc actttcctgg 
1381 gcaacaaata tgagagctgc accagcgccg gccgcagtga cggaaagatg tggtgtgcga 
1441 ccacagccaa ctacgatgat gaccgcaagt ggggcttctg ccctgaccaa gggtacagcc 
1501 tgttcctcgt ggcagcccac gagtttggcc acgccatggg gctggagcac tcccaagacc 
1561 ctggggccct gatggcaccc atttacacct acaccaagaa cttccgtctg tcccaggatg 
1621 acatcaaggg cattcaggag ctctatgggg cctctcctga cattgacctt ggcaccggcc 
1681 ccacccccac gctgggccct gtcactcctg agatctgcaa acaggacatt gtatttgatg 
1741 gcatcgctca gatccgtggt gagatcttct tcttcaagga ccggttcatt tggcggactg 
1801 tgacgccacg tgacaagccc atggggcccc tgctggtggc cacattctgg cctgagctcc 
1861 cggaaaagat tgatgcggta tacgaggccc cacaggagga gaaggctgtg ttctttgcag 
1921 ggaatgaata ctggatctac tcagccagca ccctggagcg agggtacccc aagccactga 
1981 ccagcctggg actgccccct gatgtccagc gagtggatgc cgcctttaac tggagcaaaa 
2041 acaagaagac atacatcttt gctggagaca aattctggag atacaatgag gtgaagaaga 
2101 aaatggatcc tggcttcccc aagctcatcg cagatgcctg gaatgccatc cccgataacc 
2161 tggatgccgt cgtggacctg cagggcggcg gtcacagcta cttcttcaag ggtgcctatt 
2221 acctgaagct ggagaaccaa agtctgaaga gcgtgaagtt tggaagcatc aaatccgact 
2281 ggctaggctg ctgagctggc cctggctccc acaggccctt cctctccact gccttcgata 
2341 caccgggcct ggagaactag agaaggaccc ggaggggcct ggcagccgtg ccttcagctc 
2401 tacagctaat cagcattctc actcctacct ggtaatttaa gattccagag agtggctcct 
2461 cccggtgccc aagaatagat gctgactgta ctcctcccag gcgccccttc cccctccaat 
2521 cccaccaacc ctcagagcca cccctaaaga gatactttga tattttcaac gcagccctgc 
2581 tttgggctgc cctggtgctg ccacacttca ggctcttctc ctttcacaac cttctgtggc 
2641 tcacagaacc cttggagcca atggagactg tctcaagagg gcactggtgg cccgacagcc 
2701 tggcacaggg cagtgggaca gggcatggcc aggtggccac tccagacccc tggcttttca 
2761 ctgctggctg ccttagaacc tttcttacat tagcagtttg ctttgtatgc actttgtttt 
2821 tttctttggg tcttgttttt tttttccact tagaaattgc atttcctgac agaaggactc 
2881 aggttgtctg aagtcactgc acagtgcatc tcagcccaca tagtgatggt tcccctgttc 
2941 actctactta gcatgtccct accgagtctc ttctccactg gatggaggaa aaccaagccg 
3001 tggcttcccg ctcagccctc cctgcccctc ccttcaacca ttccccatgg gaaatgtcaa 
3061 caagtatgaa taaagacacc tactgagtgg ccgtgtttgc catctgtttt agcagagcct 
3121 agacaagggc cacagaccca gccagaagcg gaaacttaaa aagtccgaat ctctgctccc 
3181 tgcagggcac aggtgatggt gtctgctgga aaggtcagag cttccaaagt aaacagcaag 
3241 agaacctcag ggagagtaag ctctagtccc tctgtcctgt agaaagagcc ctgaagaatc 
3301 agcaattttg ttgctttatt gtggcatctg ttcgaggttt gcttcctctt taagtctgtt 
3361 tcttcattag caatcatatc agttttaatg ctactactaa caatgaacag taacaataat 
3421 atccccctca attaatagag tgctttctat gtgcaaggca cttttcacgt gtcacctatt 
3481 ttaacctttc caaccacata aataaaaaag gccattatta gttgaaaaaa aaaaaaaaaa 
3541 aaaaaaaaa 
Figure 4.10 Homo sapiens matrix metallopeptidase 2 (gelatinase A, 72kDa 
gelatinase, 72kDa type IV collagenase) (MMP2), transcript variant1, 
mRNA.VERSION NM_004530.4  GI:  AUTHORS Menon,R., Pearce,B., 
Velez,D.R., Merialdi,M., Williams,S.M., Fortunato,S.J. and Thorsen,P 
(Yellow – Forward Primer; Green - Reverse Primer; Red – Probe) 128 
 
 
4.1.12  PCR Oestrogen Receptor alpha 
 
Primers and Probe from Eurogentec were used. Sequences written 5’ to 3’. 
Forward primer HESR1F: 
   TGA-TGG-GCT-TAC-TGA-CCA-ACC-T 
Reverse primer HESR1R: 
   CAA-AGC-CTG-GCA-CCC-TCT-T 
Probe HESR1T: 
   AGT-TGA-TCA-TGT-GAA-CCA-GCT-CCC-TGT-CTG 
 
The assay was set up and performed as the assays for elastin and MMP2. The 
expression of elastin, MMP2 and ERα were measured relative to the 
housekeeping gene glyceraldehyde phosphate dehydrogenase (GAPDH) to 
normalise the data to amount of RNA extracted and cDNA produced from any 
preparation. 
 
The primers and probe for GAPDH were  
Human GAPDH probe  
   TGG-AGT-CCA-CTG-GCG-TCT-TCA-CCA   
Forward primer  
   ATG-CTG-GCG-CTG-AGT-ACG-T   
Reverse primer  
   AGC-CCC-AGC-CTT-CTC-CAT 129 
 
Similarly, collagen XVII expression was measured by reverse transcription and 
real-time PCR. As the collagen XVII assay is less standard as the previous 2 
assays some details are given again – see below. 
 
 
Figure 4.11 Logarithmic Standard Curve Graph for Collagen XVII 130 
 
 
Homo Sapiens Collagen, Type XVII, alpha 1 (COL17A1), mRNA 
ORIGIN       
        1 aacatttttg aaagatcact cagctttaac acaccttggc tgggtctgga taaaaaaaaa 
       61 gtgagcactg caaatttcta gaagaaaaca tcaggagaag aaagagagag ggggatttat 
      121 tcaaagttgt ttccaattcc ttcaaaacct caaaccaggt ggctatggta tggatgtaac 
      181 caagaaaaac aaacgagatg gaactgaagt cactgagaga attgtcactg aaacagtaac 
      241 cacaagactt acatccttac caccaaaagg cgggaccagc aatggctatg ctaaaacagc 
      301 ctctcttggt ggagggagcc ggctggagaa acaaagcctg actcatggca gcagcggcta 
      361 cataaactca actggaagca cacgaggcca tgcctccacc tctagttaca ggagggctca 
      421 ctcacctgcc tccactctgc ccaactcccc aggctcaacc tttgaaagga aaactcacgt 
      481 tacccgccat gcgtatgaag ggagctccag tggcaactct tctccggagt accctcggaa 
      541 ggaatttgca tcttcttcaa ccagaggacg gagtcaaaca cgagagagtg aaattcgagt 
      601 tcgactgcag agtgcgtccc catccacccg atggacagaa ttggatgatg ttaagcgttt 
      661 gctcaagggg agtcgatcgg caagtgtgag ccccacccgg aattcctcca acacactccc 
      721 catccccaag aaaggcactg tggagaccaa aattgtgaca gcgagctccc agtcggtgtc 
      781 aggcacctac gatgcaacga tcctggatgc caaccttccc tcccatgtgt ggtcctccac 
      841 cctgcccgcg gggtcctcca tggggaccta tcacaacaac atgacaaccc agagctcatc 
      901 cctcctcaac accaatgcct actctgcggg atcagtcttc ggagttccaa acaacatggc 
      961 gtcctgctca cccactttgc accctggact cagcacatcc tcctcagtgt ttggcatgca 
     1021 gaacaatctg gcccccagct tgaccaccct gtcccatggc accaccacca cttccacagc 
     1081 atatggggtg aagaaaaaca tgccccagag tcctgcggct gtgaacactg gcgtttccac 
     1141 ctccgccgcc tgcaccacaa gtgtgcagag cgatgacctt ttgcacaagg actgcaagtt 
     1201 cctgatccta gagaaagaca acacacctgc caagaaggag atggagctgc tcatcatgac 
     1261 caaggacagc gggaaggtct ttacagcctc ccctgccagc atcgctgcaa cttctttttc 
     1321 agaagacacc ctaaaaaaag aaaagcaagc tgcctacaat gctgactcag gcctaaaagc 
     1381 cgaagctaat ggagacctga agactgtgtc cacaaagggc aagaccacca ctgcagatat 
     1441 ccacagctac ggcagcagtg gtggtggtgg cagtggagga ggtggcggtg ttggtggcgc 
     1501 tggcggcggc ccttggggac cagcgccagc ctggtgcccc tgcggctcct gctgcagctg 
     1561 gtggaagtgg ctgctgggcc tgctgctcac ctggctgcta ctcctggggc tgctcttcgg 
     1621 cctcattgct ctggcggagg aggtgaggaa gctgaaggcg cgtgtggatg agctggagag 
     1681 gatcaggagg agcatactgc cctatgggga cagcatggat agaatagaaa aggaccgcct 
     1741 ccagggcatg gcacccgcgg cgggagcaga cctggacaaa attgggctgc acagtgacag 
     1801 ccaggaggag ctctggatgt tcgtgaggaa gaagctaatg atggaacagg aaaatggaaa 
     1861 tctccgagga agccctggcc ctaaaggtga catgggaagt ccaggcccta aaggagatcg 
     1921 agggttccct gggactccag gtatccctgg gcccttgggc cacccaggtc cacaaggacc 
     1981 aaagggtcaa aaaggcagcg tgggagatcc tggcatggaa ggccccatgg gccagagagg 
     2041 gcgagaaggc cccatgggac ctcgtggtga ggcagggcct cctggatctg gagagaaagg 
 ... 
Figure 4.12 Sequence of Homo Sapiens Collagen XVII mRNA with Primer and 
Probe. Accession number NM_000494 from NCBI 
http://www.ncbi.nlm.nih.go 
(Yellow - forward primer, Green - reverse primer, Red – probe) 
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Chapter 5 :   
Results 132 
 
5.1 Racial  study 
 
Demographics for black and white women in the stress incontinence were 
assessed. Paraffin embedded vaginal skin tissue was collected from 46 women 
attending Tygerberg hospital, Cape Town. 36 women were premenopausal and 
10 menopausal (4 of the latter were taking HRT). As initial analyses showed 
secondary effects with HRT (see below), the comparison of black and white 
women and effects of stress incontinence were analysed in the premenopausal 
women alone. 
 
Four groups were established:  
  white controls (WC),  
  white stress incontinent (WS), 
  black controls (BC)  
  black stress incontinent (BS) 
 
There were 3 women who smoked in the WC and WS groups, one woman 
smoked in the BC group while none of the women in the BS group were smokers. 
However, no secondary effects for smoking were shown. Also, no secondary 
effects for parity or age on elastin staining for these women were shown. 
 
 
Summary of Demographics Stress Incontinence Study 
 
Group 
 
n 
Age 
mean(range) 
Premenopausal 
Parity 
mean(range) 
WC  10  39 (20-54)  all  2.1 (1 -4) 
WS  7  41 (34 – 47)  all  2.6 (2-4) 
BC  11  34 (23 – 42)  all  2 (0-4) 
BS  8  43 (35 – 59)  all  3.4 (2 -5) 
Table 5.1 Patients’ Details for Elastin Protein Content in Stress Incontinence in 
Different Races Study. 
 
The samples were assessed for percentage of elastin protein content using 
histochemistry staining as described earlier. 133 
 
Before the below analyses were carried out with the premenopausal women only, 
a comparison of the postmenopausal women with the premenopausal women 
was performed. 4 of the postmenopausal women in the WS group were taking 
HRT. Comparing women taking HRT within the WS group with those that were 
not showed that those women taking HRT had significantly raised elastin 
staining. Using unpaired ‘t’ test within the WS group, no HRT mean +/- SEM was 
12.6 +/- 0.97 (n=9) while with HRT mean +/- SEM was 18.2 +/- 1.63 (n=4), 
p<0.05. This suggested that HRT treatment might be having an effect on elastin 
expression.   
 
Results from the histochemistry measurements from the premenopausal women 
alone were therefore analysed using ANOVA (Analysis of variance). ANOVA 
provides a statistical calculation to assess if the means of several groups are all 
equal. It therefore generalizes Student's two-sample t-test to more than two 
groups.  
 
The percentage elastin and collagen I and collagen III content was measured 
using computer-assisted image analysis (Zeiss KS400 software, Image 
Associates, Bicester, UK) to evaluate histochemical and immunocytochemical 
staining. 
 
For all graphs in both studies: 
p  value (probability) = significance, <0.01 (highly significant), <0.001 (very highly 
significant) 
SEM = standard error of the mean 
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Figure 5.1 Results for Elastin Protein Content (Histochemistry) 
 
ANOVA comparison of the means of the different groups. (mean +/- SEM; BC 
16.74 +/- 1.26, BS 12.70+/- 1.00, WC 11.95 +/- 0.63, WS 12.19+/- 0.91) 
The ANOVA p value was p= 0.007  
 
Black women have a higher elastin protein content which decreases significantly 
if an insult to the skin such as stress incontinence has happened. Meanwhile 
white women have a lower elastin content compared with black women but white 
women with SI are not significantly different from those without SI. These specific 
comparisons are shown below.  
 
 
ANOVA p value: p= 0.007  135 
 
Elastin Protein Content in BC compared to WC 
 
Figure 5.2 Elastin protein content percentage in WC compared to BC 
 
Unpaired t-Test was used to compare the means in the two goups. (mean +/- 
SEM; WC 16.75 +/- 1.26, WC 11.32 +/- 0.63, p< 0.01). 
 
Black women without stress incontinence have a higher elastin content in 
periurethral vaginal skin compared to white women without stress incontinence. 
 
16.74
 
11.95 
mean +/- SEM; WC 16.75 +/- 1.26, WC 11.32 +/- 0.63, p< 0.01 136 
 
Elastin Protein Content in BC compared to BS 
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Figure 5.3 Elastin protein content percentage in BC compared to BC 
  
Unpaired student-t- test was used to compare the means in the two goups. 
(mean +/- SEM; BC 16.74 +/- 1.38, BS 12.7 +/- 1.031, p< 0.05)  
 
Interestingly, black women with SI showed significantly lower elastin protein 
content compared to peers with no SI.  
 
mean +/- SEM; BC 16.74 +/- 1.38, BS 12.7 +/- 1.031, p< 0.05 137 
 
Examples of the elastin staining in the 4 different groups are shown 
below. 
Figure 5.4 WC, WS, BC and BS percentage elastin content at 40 x magnification 
in comparison. Blood vessels, collagen and elastin fibres are indicated with 
arrows. 
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5.2   Results Prolapse Study 
 
Samples from 16 women before and after treatment were assessed for the 
prolapse study. The extracellular matrix components in the vaginal tissue before 
and after three months treatment with Vagifem® were examined. 
 
The age ranged between 47-84 years with a mean of 59. 14 women were non- 
smokers, 2 smoked between 5-10 cigarettes per day. One lady stopped smoking 
whilst being on the trial. Parity ranged between 2 to 4, with a mean of 2.5. The 
majority of women had spontaneous vaginal deliveries, there were no reported 
Caesarean sections and only two women had instrumental deliveries. Both were 
forceps deliveries. The women’s BMI varied between 23 to 31, with a mean of 
27.6 and was calculated using the regular formula: 
 
               weight (kg) 
      BMI =                                                               
                       height
2 (m
2) 
 
Because of the small subgroups it was not possible to show any secondary 
effects with the above variables. 
 
The percentage elastin and collagen I and collagen III content was measured 
using computer-assisted image analysis (Zeiss KS400 software, Image 
Associates, Bicester, UK) to evaluate histochemical and immunocytochemical 
staining. 
 
RNA was extracted using Trizol reagent and mRNA expression of each gene was 
measured relative to GAPDH using real time PCR for expression of MMP2, ERα, 
elastin and collagen XVII.   
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5.2.1 Molecular  Biology  Results 
 
 
MMP2 Expression 
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Figure 5.5 MMP2 RNA expression in relation to GAPDH, before and after 
Vagifem application, prolapse study 
 
Sample groups were divided into pre and post vagifem treatment groups. Paired 
student t-test was performed to compare the means in these groups. (mean +/- 
SEM; pre vagifem 0.45 +/- 0.08, post vagifem 1.22 +/- 0.16, p = 0.0016.) 
 
The MMP2 expression was highly significantly up-regulated after the use of 
Vagifem in women with POP. 
mean +/- SEM; pre vagifem 0.45 +/- 0.08, post vagifem 1.22 +/- 0.16, p = 0.0016 140 
 
Elastin mRNA Expression 
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Figure 5.6 Elastin mRNA Expression in Relation to GAPDH Expression in 
logarithmic scale before and after Vagifem Application 
 
The measured RNA expression for Elastin in the two groups was normalised with 
GAPDH, the results logarithmically transformed and Paired Student t-test was 
used to analyze and compare the means. (mean +/- SEM; pre vagifem -0.22 +/- 
0.13, post vagifem 0.14 +/- 0.11, p-value see anti-logarithmic data).  
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Anti – logarithmic transformation of this data yields a pre-treatment mean and 
SEM range of 0.6 (0.45 – 0.8) and post treatment mean and SEM range of 1.38 
(0.32 – 1.06) (see below). 
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Figure 5.7 Representation of elastin mRNA expression after the logarithmic 
transformation. Post vagifem treatment elastin mRNA expression is significantly 
higher compared to pre- vagifem treatment (p=0.034). 
p=0.034 142 
 
Collagen XVII RNA Expression 
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Figure 5.8 Collagen XVII mRNA Expression in Relation to GAPDH Expression 
 
The measured mRNA expression for Collagen XVII in the two groups was also 
normalised with GAPDH. Paired Student’s t-test was used to analyze and 
compare the means. (mean +/- SEM; pre Vagifem 1.53 +/- 0.15, post Vagifem 
0.83 +/- 0.08, p= 0.0025.) 
 
Collagen XVII was significantly decreased after three months of application with 
Vagifem. This process appears to show remodelling of the ECM as this result 
suggests reduced adhesiveness under the influence of locally applied oestradiol 
at this stage. 
 
mean +/- SEM; pre Vagifem 1.53 +/- 0.15, post Vagifem 0.83 +/- 0.08, p= 0.0025 143 
 
Oestrogen Receptor α mRNA Expression 
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Figure 5.9 Oestrogen Receptor alpha mRNA Expression in Relation to GAPDH 
Expression 
 
The measured RNA expression for ERα in the two groups was normalised with 
GAPDH. Paired Student t-test was performed to analyse and compare the 
means. (mean +/- SEM; pre Vagifem (pre) 0.95 +/- 0.095, post Vagifem (post) 
0.94 +/- 0.097, p> 0.02) The p value is 0.93 and not considered significant. 
 
mean +/- SEM; pre Vagifem (pre) 0.95 +/- 0.095, post Vagifem (post) 0.94 +/- 0.097, 
      p> 0.02 144 
 
5.2.2  Histochemstry and Immunochemistry Results 
 
Elastin protein content in percentage 
 
Figure 5.10 Elastin histochemistry results in percentage staining content, before 
and after Vagifem application 
 
Elastin percentage content was measured using histochemistry techniques. The 
means of the two groups were analysed using paired student t-test. (mean +/- 
SEM; pre Vagifem 17.44 +/- 1.22, post Vagifem 19.17 +/- 0.94, p>0.05) the p 
value is 0.27 and not considered significant. 
 
mean +/- SEM; pre Vagifem 17.44 +/- 1.22, post Vagifem 19.17 +/- 0.94, p>0.05 145 
 
 
Figure 5.11 Example for Elastin percentage content prior to Vagifem application. 
Picture at 20x magnification. Elastin fibres appear black meanwhile collagen 
fibres are red. Blood vessels can be clearly seen. 
 
 
Figure 5.12 Example for Elastin percentage content after Vagifem application. 
Picture at 20x magnification. Elastin fibres appear black and collagen fibres red. 
There is an increase in elastin content compared to figure 5.11 
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Collagen I Protein Content in Percentage, Immunocytochemistry 
Results 
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Figure 5.13 Collagen I Protein Content in Percentage 
 
The percentage content of collagen I in the two groups was, as the elastin 
content, measured with Zeiss system analysis. Paired Student t-test was used to 
analyse and compare the means. (mean +/- SEM; pre Vagifem (pre) 28.71 +/- 
1.21 post Vagifem (post) 33.54 +/- 0.96, p< 0.02) The p value was 0.0003. 
 
mean +/- SEM; pre Vagifem 28.71 +/- 1.21 post Vagifem 33.54 +/- 0.96, p< 0.02 147 
 
Figure 5.14 Collagen I fibres before treatment with Vagifem. The fibres appear 
brown and are surrounded by blood vessels and capillaries. Purple black cell 
nuclei are visible in this x20 magnification. 
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Figure 5.15 Collagen I fibres in x20 magnification from vaginal wall tissue after 
Vagifem application. In comparison to Figure 5.15, collagen fibres appear more 
dense. 
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Collagen III Protein Content in Percentage 
Collagen III percentage protein content
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Figure 5.16 mean and SEM of Collagen III protein, pre and post Vagifem 
application. 
 
The collagen III percentage protein content in the two groups was measured with 
Zeiss system analysis. Paired Student t-test was used to analyse and compare 
the means. (mean +/- SEM; pre Vagifem (pre) 31.47 +/- 0.88, post Vagifem (post) 
38.4 +/- 0.89, p= 0.0002.) 
 
Collagen III was found to be increased significantly after Vagifem application 
similar to collagen I. This finding complements the elastin results and 
demonstrates increased elasticity to support the prolapsed tissue and prevent 
further damage. 
 
mean +/- SEM; pre Vagifem (pre) 31.47 +/- 0.88, post Vagifem (post) 38.4 +/- 0.89, 
 p= 0.0002 150 
 
 
Figure 5.17 Collagen III staining of vaginal skin in a woman with POP prior to 
Vagifem application. Collagen III stains in brown. Fibroblasts are also identified. 
Microscope amplification used for this picture was 20X. 
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Figure 5.18 Collagen III (C III) staining of vaginal skin from same woman as seen 
in Figure 5.17 after Vagifem application. Dense collagen III formation can be 
seen with this staining. Blood vessels (BV) are seen in the connective tissue. 
Microscope amplification is x20 
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Collagen I:III Ratio Protein Content Percentage  
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Figure 5.19 mean and SEM of Collagen I:III ratio, pre and post Vagifem 
application. 
 
The percentage protein content of collagen I in relation to percentage protein 
content of collagen III in the two groups was measured with Zeiss system 
analysis. Paired Student t-test was used to analyse and compare the means. 
(mean +/- SEM; pre Vagifem (pre) 0.92 +/- 0.05, post Vagifem (post) 0.88 +/- 
0.03, p> 0.02) The p value is 0.41 and not considered significant. 
 
Interestingly, both Collagen I and Collagen III content increased under the 
influence of Vagifem and the collagen I:III ratio was not changed significantly. 
 
mean +/- SEM; pre Vagifem (pre) 0.92 +/- 0.05, post Vagifem (post) 0.88 +/- 0.03, p> 0.02 153 
 
Results overview 
 Pre   
mean (+/- SEM) 
Post  
mean (+/- SEM) 
P value  n 
MMP2 mRNA  0.45 (0.078)  1.22 (0.16)  0.0016**  16 
Elastin mRNA (anti 
log) 
0.6 (0.45-0.8)  1.38 (0.32-1.06)  0.034  16 
Elastin protein   17.44 (1.22)  19.17 (0.94)  0.27  16 
CollagenXVII mRNA  1.53 (0.15)  0.83 (0.08)  0.0025**  16 
ERalpha mRNA  0.95 (0.095)  0.94 (0.097)  0.93  16 
Collagen I protein   28.71 (1.21)  33.54 (0.96)  0.0003***  16 
Collagen III protein  31.47 (0.88)  38.4 (0.89)  0.0002***  16 
Collagen I:III ratio  0.92 (0.05)  0.88 (0.03)  0.41  16 
Table 5.2 Result Overview for the Prolapse Study 
 
 
 
5.3 Summary   
5.3.1  Racial and Stress Incontinence Study 
 
It was established that black women have a higher elastin content in their 
periurethral vaginal tissue than white women. As predicted black women with 
stress incontinence had a lower elastin level than black women without SI. 
However, the connective tissue of white women appeared to respond differently 
than that of black woman as white women with stress incontinence did not have 
significantly different levels of elastin staining compared to white controls. 
However, white women can have secondary effects as postmenopausal women 
on HRT appeared to have higher elastin levels but if this was an oestrogen effect, 
the following Vagifem study was necessary to prove this. What secondary effects 
were occurring in the premenopausal white women was not established. 
However, it could be that black women have the possibility to withstand pelvic 
floor dysfunction more successfully because of their higher elastin levels. 154 
 
Increased elasticity would support the tissue and induce more resilience to 
changes due to stress to the tissue. 
 
 
5.3.2 Prolapse  Study 
 
We could show that locally applied oestrogen up-regulates the message (mRNA) 
for MMP2 necessary for tissue remodelling after stress. Although the message 
for ERα was found in vaginal skin and therefore had the potential to respond to 
topical oestrogen ERα mRNA remained unchanged after Vagifem administration, 
contrary to original predictions. The message for the adhesive collagen, collagen 
XVII, was down-regulated significantly probably contributing to tissue 
remodelling. However, collagen I protein staining was increased significantly, 
suggesting new synthesis. Interestingly, mRNA for elastin was also significantly 
elevated after 3 months of Vagifem treatment but the increase in protein elastin 
staining did not quite reach significance. Overall this small trial provides some 
evidence that topical oestrogen has beneficial effects on message and protein 
production of key factors involved in tissue remodelling to improve vaginal tissue 
characteristics. 155 
 
 
 
 
 
Chapter 6 :   
Discussion 156 
 
Our hypothesis that black women would express higher elastin levels in vaginal 
tissue than white women has been found to be correct. This is an original finding 
and supports results from a previous study in this research group which saw 
lower collagen I in respect to collagen III in black women compared with white. 
Together, results indicate higher elasticity in vaginal tissue of black women. This 
hypothesis was put forward as black women have been considered to be more 
resistant to stress incontinence and vaginal prolapse. An increased elasticity of 
the tissue would enable it to compensate more appropriately when there is stress 
on the tissue. 
 
As also discussed in the Introduction, previous studies have demonstrated that 
black women have a lower prevalence of pelvic floor dysfunction such as stress 
incontinence or POP.
148 Some inherent anatomical and physiological differences 
have been widely established in the past. For instance, in these studies black 
women were shown to have a higher bone mass density and muscle mass and 
have a lower incidence of bone fracture and trauma to the connective tissues.
 149 
Bone remodelling appears to be different and together with a modified calcium 
metabolism osteoporotic fractures are less common among black women. 
Studies using MRI established that black women have a larger levator ani volume 
and a closer attachment of the puborectalis muscle compared to white women. 
The different muscle volume and position resulted in a variation of bladder neck 
position, urethral angle and pubic arch angle. Other studies demonstrated a 
longer urethra and higher urethral closure pressure. The increased elasticity of 
the vaginal tissue would thus add to a list of beneficial adaptations that are 
present in and around the vagina of black women to help them resist stress 
incontinence and vaginal prolapse. Fitting with the above advantages pelvic 
ligaments of black women with prolapse show greater collagen content compared 
to white peers
150 and black women tend to have a lower incidence of perineal 157 
 
tears during vaginal birth, demonstrating higher tissue resilience.
151 Interestingly, 
black women also tend to have a higher incidence of uterine fibroids, keloid scars 
and striae
33 than white women supporting the presence of a different skin 
extracellular matrix make-up in black women. 
 
The next hypothesis in this thesis was that in stress incontinent women elastin 
content would change in reaction to stress. This was indeed confirmed in black 
women where stress incontinence coincided with significantly lower elastin levels 
than control. However, elastin content remained unaltered in white SI or control 
women. We currently don’t have a specific explanation for this but confounding 
factors or secondary effects should be considered. 
 
Chen et al examined periurethral vaginal wall fibroblasts from premenopausal 
women with stress urinary incontinence and compared these to fibroblasts form 
continent women. Total elastase activity was measured by generation of free 
amino groups from succinylated elastin. It appeared that elastase activity was 
increased in relaxin-stimulated stress urinary incontinence fibroblasts by either 
decreased inhibitor (alpha-1 antitrypsin) production or increased elastase 
activity
127. Another study by Chen showed a significant decrease in alpha-1 
antitrypsin expression in tissues from women with SUI/POP compared to 
controls. Collectively, data suggests that altered elastin metabolism may 
contribute to the connective tissue alterations observed in pelvic floor 
dysfunction.
152 This increase in elastase could explain the decrease in elastin in 
black incontinent women but for the case of white women with stress 
incontinence perhaps other factors inhibit the elastase activity. 158 
 
Laborda et al demonstrated that Collagen XVII which is an adhesive molecule 
contributing to tensile strength was expressed in higher quantities (mRNA 
measurements) in the vaginal wall skin of black women compared to white
36. 
These latter findings proposed that black women have elevated adhesiveness. 
Therefore it was decided to examine elastin protein content in the vaginal skin of 
women from different races with and without stress incontinence to show 
improvements in elasticity as well. 
 
Elastin is an amorphous protein and belongs to the group of elastic fibres 
including elaunin and oxytalan. They are produced by fibroblasts and smooth 
muscle cells in arteries. Extension can reach up to 1.5 times of the basic length, 
and recoil without major damage to the original length when relaxed. The elastic 
fibre consists of microfibrils which build a scaffold for the elastin protein. These 
microfibrils are assembled as numerous proteins such as microfibrillar-associated 
glycoproteins, fibrillin, fibullin. 
 
The increased elastic property of the tissue in black women seems to protect the 
tissue from damage for a longer period of time but the remodelling process after 
damage occurred may be less active. Higher elastin content could be 
accountable for the reduced risk of perineal tears during vaginal child birth in 
black women but the tendency to have keloid scars could be a sign that the 
remodelling process of the tissues once damage is present is not effective 
anymore. Collagen III is inserted into the scar tissue in replacement of collagen I 
supposedly giving a higher elasticity of the tissue but without the vigour of normal 
scar tissue. The tissue appears to restructure itself and regain the previous 
quality of elasticity and strength but is not capable of achieving satisfactory 
results. 
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The main study population contained only pre-menopausal women hence 
excluding potential hormonal differences due to menopause. Hormonal 
influences are important confounders since in a small subgroup of 
postmenopausal women HRT caused an elevation of elastin levels in white 
incontinent women. Other parameters influencing extracellular matrix 
components such as smoking, BMI, diet and life style were examined similarly 
but no significant secondary effects were evident. 
 
The second study in this thesis was designed after the first study showed that 
increased elasticity in black women may be a major reason for the lower 
prevalence of stress incontinence and prolapse in these women. Hormonal 
influences are also relevant as in a small group of postmenopausal women on 
HRT higher levels of elastin were observed. Therefore, it was hypothesised that 
in postmenopausal women with vaginal prolapse oestrogen (Vagifem) would 
increase elastin mRNA and protein levels. 
 
In the present thesis study, women with at least POP stage 2 were recruited and 
ECM changes were assessed in the prolapsed vaginal wall tissue before and 
three months after application of Vagifem, containing 25mcgr 17β oestradiol. 
Three months of oestradiol treatment changed the expression and protein 
content of ECM components in the vaginal skin. Collagen I and III protein content 
in the vaginal skin increased both significantly leaving the collagen I:III ratio 
unaltered. Importantly elastin mRNA was found to be elevated three months after 
Vagifem treatment. Elastin protein level, although also higher after oestrogen 
treatment, did not quite reach significance. However, the study only lasted three 
months and one would anticipate that after six months the elastin staining would 
be more pronounced. Jackson et al studied administration of oestrogen for six 
months in postmenopausal women with stress incontinence and found new 160 
 
collagen was being synthesised by then and also pro-MMP2 was up regulated to 
assist in tissue remodelling. This fits well with the up regulation of MMP2 mRNA 
levels after three months in the present work. The present study also showed a 
significant reduction in the adhesive collagen, collagen XVII. Presumably this 
would aid in remodelling, although this collagen would have to be up regulated 
eventually when the ECM had been remodelled adequately to establish tissue 
integrity.  
 
To avoid confounding hormonal influences, only post-menopausal women were 
recruited for the study. A two year gap since last menstruation or the 
discontinuation of hormone replacement therapy of any kind for at least six 
months had to be ensured. As explained in the introduction, no hormonal 
supplemental medication should be used, obviously, yet HRT plays a large role in 
the management of postmenopausal symptoms and in the prevention of 
osteoporosis in postmenopausal women. It therefore proved to be quite difficult to 
recruit women fulfilling the criteria for this study. Also, many women were referred 
for recurrent prolapse repair surgery as the Princess Anne Hospital in 
Southampton is a tertiary unit. These patients also needed to be excluded. As 
also demonstrated in previous studies, many women presenting with POP also 
experience stress incontinence symptoms. Stress incontinence on its own can 
alter the pelvic floor and therefore extracellular matrix organisation. Patients with 
SI symptoms or urodynamically proven SI were not recruited. 
 
One further impediment was the precaution of women using hormone 
supplements. The fear of side effects such as breast cancer prevented many 
women to take part in the study unless they were placed in the control group. 
Even detailed and reassuring counselling with the use of patient information 
leaflets did often not help to change patients’ mind. As recruitment was difficult 161 
 
for the above reasons the setting up of a control group was not easy and the 
manufacturers of Vagifem could not produce any placebo pessaries in time. 
Therefore, the patients had to act as their own control group of pre and post 
treatment. However, we considered the design still adequate since a previous 
study by Jackson had shown that the production of new collagen and pro-MMP2 
was due to oestrogen treatment as the placebo control group that ran alongside 
the study group remained unchanged. 
 
The aetiology of prolapse is still poorly understood. Theories of factors to 
increase the risk of developing POP include muscular or neurological injury 
especially occurring during child birth
153, obesity, smoking and family 
predisposition. Rahn et al showed in an animal study that matrix metalloprotease 
(MMP) activity is increased in the postpartum vagina of wild-type (WT) animals. 
This derivative activity is also accompanied by an increase of elastic fibre 
synthesis and assembly. 
154 
 
Oestrogen plays an important role in maintenance of the pelvic floor tissues and 
appears to improve hydration and strength of skin. It was shown that a decrease 
in sex steroids induces a reduction of those skin functions that are under 
hormonal control.
 155As an opposite effect, topical oestrogen improves elasticity 
and collagen turnover.
156 Shah and Maibach showed that skin is thinning with 
age and that topical oestrogen is slowing down this effect. Further, DNA 
synthesis is stimulated in human epidermal keratinocytes by oestradiol which was 
shown by Urano et al in 1995. There are different effects of oestrogen via multiple 
oestrogen receptors both, intra cellular as the known steroid receptors (here ERα 
and ERβ) or as transmembrane receptors. Latter being supported by groups 
showing an effect of oestradiol on human epidermal keratinocytes, with 
increasing phosphorylisation levels of ERK1 and ERK2 kinases within 15 162 
 
minutes.
157 It will be interesting to investigate this further and determine if vaginal 
skin also not only reacts via ERα and ERβ receptors but also through membrane 
bound equivalents. In the present study it was hypothesised that the mRNA for 
ERα would be upregulated after oestrogen treatment. Although elastin and 
MMP2 mRNA were increased ERα was not. However, we could show that the 
vaginal skin was producing mRNA for ERα permitting responsiveness to 
oestrogen either through intracellular and genomic action or through 
transmembrane receptors. 
  
It has been found that hormone replacement therapy (HRT) increases epidermal 
thickness in female human epidermal skin after six months of oral oestrogen 
intake
158 and also increases hydration of skin whether being applied orally or 
topically.
159 ,
160 Furthermore, in a randomized, double blind, placebo controlled 
trial carried out by Sauerbronn et al in 2000, an increase of 6.49% of collagen 
content in epidermal human skin was demonstrated after six months of treatment 
with oral oestrogens.
161. A study by Brincat et al undertaken in 1987 confirms the 
findings. It further shows that in women with initial low collagen content, 
oestrogen is initially therapeutic at first but later becomes solely prophylactic 
whilst in women with only mild collagen loss it is only prophylactic. The optimum 
collagen content was seen after two years of oestrogen treatment in this study 
which examined a time period of two to ten years of treatment.
162 The same 
effects were demonstrated in topical application of oestrogen in 1995 by Varila et 
al. Further, an increase in collagen synthesis was demonstrated with raised 
collagen I and III levels. The same group also was able to show an increase in 
tropoelastin and fibrillin mRNA in skin of males and females and a decrease in 
MMP1 expression. The most important difference to systemically applied 
oestrogen is that topical oestrogen appears to only be effective on the area it is 
applied to. 
163 
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Tissues of the pelvic floor act rather similarly when it comes to oestrogen 
response even though the histology is somewhat different. Keane et al showed 
that vaginal skin and endopelvic fascia have similar properties
136 and so vaginal 
wall tissue was examined assuming similar changes to the endopelvic fascia. 
Whether all of these effects found in epidermal skin could also apply for vaginal 
skin in prolapsed vaginal tissue is therefore of interest. Changes through 
oestrogen application as described so far would not only help with current 
symptoms but may slow down the destructive change in the prolapsed tissue and 
maybe in future studies could be used to prevent prolapse altogether. Medication 
that was easy to apply was used in present studies. Creams and oestrogen 
releasing vaginal rings are known to be difficult to use in vaginal prolapse. The 
application is more difficult as rings tend to fall out and creams are not reliable as 
the amount used cannot be measured reliably and varies significantly, even when 
administered with an applicator. The use of a small pessary that can be inserted 
with an applicator into the posterior vaginal fornix was easiest. As each pessary 
contains the amount of 25μg 17β-oestradiol the same amount of medication is 
used by each woman. Furthermore, 17β-oestradiol is an oestrogen that the body 
is familiar with and has a proven effect in atrophic vaginitis and thus the best 
option for use in this study.  
 
A very recent study from 2009 by Soederberg
165 et al examined expression of 
small leucine-rich repeat proteoglycans and fibulin-5 in para-vaginal tissue of 
women with pelvic organ prolapse. The group found a 16 fold decrease in 
decorin mRNA expression (P=0.0001) and an 8 fold decrease in lumican 
expression (P=0.001) in pre-menopausal women. All women with POP showed 
lower gene expression of fibromodulin and fibulin-5, the latter being an elastin 
associated protein. Thus a substantially decreased expression for regulators of 164 
 
collagen fibre assembly and impairment in elastic fibre assembly was detected 
through down regulation of fibulin-5. The women were partly pre-and post 
menopausal leaving the question open whether hormonal profiles masked the 
results. Other studies, conducted in 2006 by Goepel et al
166, showed that 
paravaginal tissue from stress incontinent women showed fragmented distribution 
of elastin. Further studies could examine more closely which elastin fragments 
are affected by oestrogen to establish more focused support. 
 
As oestrogen appears to be effective and improve skin of menopausal women 
(see above) and as shown in our study, ECM constituents of vaginal skin as well, 
the question is now could the type of oestrogen be more appropriately tailored to 
enhance the beneficial effects. A more tailored oestrogen derivative perhaps 
belonging to the group of Selective Estrogen Receptor Modulators (SERMs) 
could now be studied or perhaps even a cocktail of SERMs that promote different 
characteristics. Maybe, for instance,one would lower the collagen XVII for 
remodelling while another increased collagen XVII and adhesiveness after the 
reshaping and remodelling had taken place. It is known that SERMs can 
modulate oestrogen receptors in a tissue specific manner and are acting 
differently on varying tissues. Tamoxifen, a non-steroidal triphenylethylene is 
widely used in the management of hormonally responsive breast cancer. There it 
acts as an antagonist of oestrogen whereas in endometrial tissue it is a strong 
agonist and thus increases the risk of endometrial cancer by three fold 
167. 
Overall SERMs act as agonists for tissues such as bone, liver and the 
cardiovascular system, while their antagonistic effects are shown in brain and 
breast tissue. Yet, they have mixed effects on uterine tissue. Raloxifene, a 
benzothiopene, lacks uterotrophic activity and can thus be used as prevention of 
osteoporosis without these side effects.  
 165 
 
The differences are found in the action of the SERMs. Tamoxifen for example 
activates the AP 1 target gene in uterine cells whereas raloxifene does not have 
this ability. SERMs act on skin. It is known that the expression of ERα and ERβ 
expression are modulated by tamoxifen and raloxifene
168 It is important to 
understand how SERMs also act on different tissue types to help create new 
SERMs with more favourable profiles, selected efficacy and side effect 
characteristics.  
 
In conclusion, we were able to show that black women have preferential 
expression of elastic components that are likely to contribute to the lower 
prevalence of stress incontinence and pelvic organ prolapse compared with white 
women.  In white women with vaginal prolapse an increase in remodelling and 
expression of elastin was found with the support of oestrogen in order to try and 
promote some of the beneficial characteristics of a black woman’s vaginal skin. 
Perhaps these beneficial effects could be enhanced further with alternative 
oestrogen type compounds or by adding growth factors or cytokines that can also 
promote ECM synthesis. Further enhancement could occur with the use of matrix 
type scaffolds that are presently being investigated with different tissues (stem 
cell seeding is also being investigated with such scaffolds). A combination of 
such techniques could well be the future for alleviating the suffering associated 
with pelvic organ dysfunction. The present studies help to identify optimum 
characteristics to resist stress incontinence and pelvic organ prolapse and show 
the ability of oestrogen type compounds to produce some of the beneficial 
characteristics.  
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1. How would you describe your health at the present? 
                                                                  Please tick one answer  
               
                                     Very good 
 
                                     Good 
 
                                     Fair 
 
                                     Poor 
 
                                     Very poor 
 
 
 
 
2.  How much do you think your prolapse problem affect your life? 
 
                                                                Please tick one answer 
 
 
                                   Not at all 
 
                                   A little 
 
                                   Moderately 
 
                                   A lot 
                                                                                                                                                                 
                                   
 
 
 
 
 
                                                                                                   Please turn the page 
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2. Below are some daily activities that can be affected by prolapse 
problems. How much does your prolapse problem affect you? We 
would like you to answer every question. Simply tick the box that 
applies to you 
 
                                                         1              2                3                4              
3. ROLE LIMITATIONS                         Not at all   Slightly   Moderately  A lot      
  
A. Does your prolapse problem affect your  
     household tasks?  
    (e.g. cleaning, shopping etc.) 
 
B. Does your prolapse problem affect your 
     job, or your normal daily activities 
    outside the home? 
 
                                                                             1              2                3               4 
4. PHYSICAL/SOCIAL LIMITATION  Not at all  Slightly   Moderately  A lot      
 
A  Does your prolapse problem affect 
     your physical activities (e.g. going  
     for a walk, running, sport, gym etc)? 
 
B. Does your prolapse problem affect  
     your ability to travel? 
 
C. Does your prolapse problem limit  
     your social life? 
 
D. Does your prolapse problem limit 
     your ability to see and visit friends?              193 
 
 
5. PERSONAL RELATIONSHIPS   0            1               2              3                  4          
               Not    Not at all  Slightly  Moderately   A lot      
                               Applicable                                                            
 
A. Does your prolapse problem  
     affect your relationship with  
     your partner? 
 
B. Does your prolapse problem   
     affect your sex life? 
 
C. Does your prolapse problem  
     affect your family life?                                                                                                                       
 
                                                                                                                   
                                                                      1                 2                   3                    4    
6. EMOTIONS                                    Not at all     Slightly      Moderately     Very 
                             m u c h      
 
A. Does your prolapse problem make  
     you feel depressed?      
 
B. Does your prolapse problem make 
     you feel anxious or nervous? 
 
C. Does your prolapse problem make  
     you feel bad about yourself? 
 
 
                                                            1                 2                    3                4 
7.SLEEP/ENERGY                               Never      Sometimes      Often        All the 
                           t i m e  
 
A. Does your prolapse problem 
     affect your sleep? 
 
B. Does your prolapse problem make 
     you feel worn out and tired ? 
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8.Do you do any of the following to help your prolapse problem? If so how 
much?   
 
                                                                     1               2               3                 4 
                                                                Never   Sometimes   Often    All the time 
A. Use tampons/pads/ firm knickers 
 
B.  Do you push up the prolapse?  
    
C. Do you have pain due to the 
     prolapse? 
 
D. Does the prolapse prevent you from 
     standing? 
 
 
 
 
 
                                 195 
 
 
 
 
3. We would like to know what your prolapse problems are and how 
much they affect you. From the list below choose only those 
problems that you have at present. Leave out those that don’t apply 
to you. 
 
How much do they affect you? 
FREQUENCY: going to the toilet very often 
1.  Not applicable      2. A little     3. Moderately      4. A lot       
  
 
 
NOCTURIA: getting up at night to pass urine 
1. Not applicable    2. A little     3. Moderately      4. A lot        
 
 
 
URGENCY: a strong and difficult to control desire to pass urine 
1.  Not applicable    2. A little     3. Moderately      4. A lot       
  
 
 
URGE INCONTINENCE: urinary leakage associated with a strong desire to pass 
urine 
1. Not applicable    2. A little     3. Moderately      4. A lot        
 
 
 
STRESS INCONTINENCE: urinary leakage with physical activity eg. coughing, 
running 
1.  Not applicable      2. A little     3. Moderately      4. A lot       
  
 
 
Feeling a bulge/lump from or in the vagina 
1. Not applicable    2. A little     3. Moderately      4. A lot        
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Heaviness or dragging feeling as the day goes on from the vagina or the lower 
abdomen 
1.  Not applicable  2. A little     3. Moderately      4. A lot       
  
 
 
Vaginal bulge interfering with you emptying your bowels 
1. Not applicable    2. A little     3. Moderately      4. A lot        
 
 
 
Discomfort in the vagina which is worse when standing and relieved by lying 
down 
1.  Not applicable      2. A little     3. Moderately      4. A lot       
  
 
 
Poor urinary stream 
1.  Not applicable     2. A little     3. Moderately      4. A lot       
  
 
 
Straining to empty your bladder 
1. Not applicable    2. A little     3. Moderately      4. A lot 
 
 
 
 
Urine dribbles after emptying after emptying your bladder 
1.  Not applicable      2. A little     3. Moderately      4. A lot       
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3a. Please write down if you have any of the following symptoms and 
mark how much these affect you.  
 
Bowel not feeling completely empty 
1. Not applicable    2. A little     3. Moderately      4. A lot        
 
 
Constipation, difficulty in emptying your bowels 
1.  Not applicable   2. A little     3. Moderately      4. A lot       
  
 
Straining to open your bowels 
1. Not applicable    2. A little     3. Moderately      4. A lot        
 
 
Vaginal bulge which gets I the way of sex 
1.  Not applicable      2. A little     3. Moderately      4. A lot       
  
 
Lower backache worsens with vaginal discomfort 
1. Not applicable    2. A little     3. Moderately      4. A lot        
 
 
Do you help emty your bowels with your fingers? 
1.  Not applicable      2. A little     3.Moderately      4. A lot   
     
  
 
How often do you open your bowels? 
1. More than          2. Once a day      3. Once every          4. Once/week 
     Once/day                             two days                 or more 
 
 
 
 
Thank you for your time!198 
 
 
 
 
 
 To Calculate Scores 
 
PART 1 
 
1) General Health Perceptions 
Very good  1 
Good   2 
Fair   3 
Poor   4 
Very poor  5 
Score = ((Score to Q1 – 1)/4) x 100 
2) Prolapse  Impact 
 
Not at all   1 
 
     A little    2 
 
     Moderately  3 
 
     A lot    4 
Score =((Score to Q2 – 1)/3) x 100 
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PART 2  
Individual scores as recorded at the top of each column of possible 
responses 
3) Role limitations 
Score =(((Scores to Q 3A + 3B) – 2)/6) x 100 
4) Physical limitations 
Score =(((Scores to Q 4A + 4B) – 2)/6) x 100 
5) Social limitations 
[If 5C >/= 1]  Score = 
(((Score to Q 4C + 4D + 5C)  – 3)/9) x 100  
[If 5C = 0]     Score = 
(((Score to Q 4C + 4D) – 2)/6) x 100  
6) Personal relationships 
[If 5A+5B >=2] Score = 
(((Scores to Q 5A + 5B) – 2)/6) x 100 
[If 5A+5B =1]  Score = 
(((Scores to Q 5A + 5B) – 1)/3) x 100 
[If 5A+5B =0]  Treat as missing value 
7) Emotions 
Score = (((Score to Q 6A + 6B + 6C)  – 3)/9) X 100  
8) Sleep / energy 
Score =  (((Scores to Q 7A + 7B) – 2)/6) x 100 
9) Severity measures 
Score = (((Scores to Q 8A + 8B + 8C + 8D) – 4)/12) x 100 200 
 
PART 3 
  Scale    score 
  N/A         0 
  A little        1 
 Moderately       2 
 A  lot        3 
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Symptom questionnaire pre and post surgery 
 
Pre surgery 
 
 
    Obstetrics  and  Gynaecology  Directorate 
     Urogynaecology 
       G  Level,  Mailpoint  105 
       P r i n c e s s   A n n e   H o s p i t a l  
       C o x f o r d   R o a d  
       Southampton  SO16  5YA 
 
       Tel:  023  8079  8967 
       Fax:  023  8079  4801 
 
 
A randomised trial examining the influence of vaginal oestrogen on 
symptoms, signs, connective tissue metabolism and surgical outcome 
in wo men with prolapse. 
 
 
Pre-operative symptoms questionnaire 
 
 
Visit 1 □                              at time of surgery (3 months) □ 
 
 
Name: __________________________ DOB: ______________ 
 
Profession: _______________________ 
 
Weight: _______________ 
 
 
Hormonal status pre-operatively: 
 
HRT:        opposed □ unopposed  □ 
 
Topical oestrogen:  Vagifem □ other  □ ___________________ 
 
Medical history: 
 
 
 
 
Surgical history:        Chronic cough:        Y □ N  □   202 
 
Obstetric history: 
 
Parity  Birth weight  Mode delivery  Episiotomy/Tear  PFE 
     
     
     
     
 
 
Symptoms pre-operatively: 
 
Prolapse:       Dragging sensation □ 
 
  Pain/  discomfort  □ 
 
    Awareness of a lump □ 
 
  Backache  □ 
  
Urinary:  
 
Urgency:   mild  □   moderate  □      severe □  
 
Urge incontinence:  mild □   moderate  □   severe  □   
 
Frequency:   voids/day_______ 
 
Incomplete emptying: Y □   N  □ 
 
Stress incontinence:  Y □   N  □  
 
Nocturia:   voids/night_______ 
 
Recurrent UTIs:  Y □   N  □ 
 
Voiding difficulties:  straining □   poor stream □   incomplete emptying □ 
 
Bowel function: normal □     constipation □ loose  □   recent change □ 
 
Mechanics: normal  □ straining  □ laxatives  □         
 
Digitation:       none □     vaginally  □ rectally  □ 
 
Incontinence: none  □   gas □    liquid□       solid □     
  
Rectal symptoms:  bleeding □ 
 
Soiling:     Y  □   N  □ 
 
Difficulty wiping clean:     Y □   N  □ 
 
 
Sexual functions:   not active □   no problems □   dyspareunia  □ 
 
lack of sensation □   dryness □ 203 
 
 
 
 
 
 
Examination: 
 
Aa Ab C 
Gh Pb Tvl 
Pa Bp D 
 
 
Vulval skin:      healthy □       red □         sore□                 excoriated □ 
 
Vaginal mucosa:  well oestrogenised  □ poorly  oestrogenised  □       atrophic □ 
 
Perineum:     healthy □     scarred □      atrophic □ 
 
Vaginal capacity:       normal □      reduced  □ 
 
Pelvic floor contraction:   nil □        flicker □       moderate □      good □        strong □  
 
Pelvic floor exercises pre op:     Y □     N □ 
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Post surgery 
 
 
     Obstetrics  and  Gynaecology  Directorate 
       U r o g y n a e c o l o g y  
       G  Level,  Mailpoint  105 
       P r i n c e s s   A n n e   H o s p i t a l  
       C o x f o r d   R o a d  
       Southampton  SO16  5YA 
 
       Tel:  023  8079  8967 
      Fax:  023  8079  4801 
 
A randomised trial examining the influence of vaginal oestrogen on 
symptoms, signs, connective tissue metabolism and surgical outcome 
in women with prolapse. 
 
Post-operative symptoms questionnaire 
 
Visit 2 (6/52 post op) □    Visit 3 (3 months post op) □   Visit 4 (6 months post op) □    Visit 
5 (12 months post op) □ 
 
Name: __________________________ Dob: ______________  Age:___ 
 
Profession: _______________________ 
 
Weight: ______   Operation date:____________ 
 
Surgeon: ________________ 
 
Type of Surgery:    anterior repair □       posterior repair □       ant.& post. repair □ 
 
Use of Mesh:  anterior □ posterior  □ 
 
Other procedure: ______________________________________________________ 
 
Prolapse recurrence:    Y □   N □ 
 
Anaesthesia: GA  □   Spinal  □  LA  □ 
 
Complications intra/post op:_____________________________________________ 
 
Time to recover to normal activity:______________________ 
 
Symptoms post-operatively: 
Prolapse:       Dragging sensation □ 
  Pain/  discomfort  □ 
    Awareness of a lump □ 
  Backache  □ 
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Urinary:  
 
Urgency   mild  □   moderate □      severe □  
 
Urge incontinence  mild □   moderate □   severe  □   
 
Frequency   voids/day_______ 
 
Stress incontinence  Y □   N  □  
 
Nocturia:   voids/night_______ 
 
Recurrent UTIs  Y □   N  □ 
 
Voiding difficulties  straining □   poor stream □   incomplete emptying □ 
 
Bowel function:  normal □     constipation □ loose  □   recent change □ 
 
Mechanics: normal  □ straining  □ laxatives  □         
 
Digitation:      none □    vaginally □ rectally  □ 
 
Incontinence: none  □    gas □     liquid□       solid □      
 
Rectal symptoms:  bleeding □ 
 
Soiling:   Y □   N  □ 
 
Difficulty wiping clean:   Y □   N □ 
 
 
Sexual functions:  not active □   no problems □   dyspareunia □ 
 
lack of sensation □   dryness □ 
 
Examination: 
Aa Ab C 
Gh Pb Tvl 
Pa Bp D 
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Vulval skin:    healthy □       red □         sore□                 excoriated □ 
 
Vaginal mucosa:  well oestrogenised □ poorly  oestrogenised  □       atrophic □ 
 
Perineum:   healthy □    scarred □      atrophic □ 
 
Vaginal capacity:       normal □      reduced  □ 
 
Pelvic floor contraction:   nil □        flicker □       moderate □      good □        strong □  
 
Pelvic floor exercises post op:   Y □    N □ 
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QoL Summary: 
 
Overall 49 women were recruited for the study to assess the symptoms and quality 
of life before and after Vagifem treatment. 
The power calculation demonstrated that 105 women were needed: 
 
If we use symptom reduction as an outcome measure and we postulate a 40% 
reduction in symptoms (we would expect more) with a power of 0.8 and a 
significance level of 0.05 we need 30 women in each arm. 
The recurrence rates of prolapse are reported as high as 40% at one year.  Using 
similar calculations we should have sufficient patients to detect a significant 
difference despite dropouts. 
The final data would still need to be collected to establish statistical significance and 
report a change in symptoms as well as a reduction in recurrence rate of pelvic 
organ prolapse with Vagifem treatment. The study will be followed up to complete 
the data.  
 
Overview over Methods from original trial protocol: 
The patients for the study will be recruited from the waiting list for an anterior and or 
posterior repair in the Princess Anne Hospital.  We will randomise 105 post-
menopausal women.  Patients with previous vaginal surgery, history of malignancy, 
collagen diseases and stress incontinence will be excluded.  Patients will be asked 
to fill a QoL (quality of life) questionnaire and a standardised symptoms 
questionnaire.  A vaginal examination to assess the stage of prolapse will be 
performed in accordance with the ICS standard (POP Q score). Then they will be 
randomised in two groups, the study group and the control group in a 2:1 ratio, 
respectively. The study group will receive a pelvic ultrasound scan to measure 
endometrial thickness and will be treated with topical vaginal oestrogens (25 mcg of 208 
 
oestradiol pessaries twice weekly) and the control group will receive no treatment. A 
small punch biopsy (5mm x 5mm) from vaginal skin will be obtained under local 
anaesthetic from the patients in the study group. After three months of treatment 
surgery will be performed and a second biopsy will be obtained during the procedure 
from patients in the study group only and 4mls of blood will be obtained by venous 
puncture to assess the oestrogen blood level. 
All the biopsies will be analysed for: 
1.  Collagen metabolism by measuring matrix metalloproteinases activity and their 
inhibitors. 
2.  The expression of the matrix remodelling cytokines within the tissue. 
3.  Immunocytochemistry staining for the ratio of collagen I:III. 
4.  Oestrogen receptor expression in the tissues. 
The patients in the study will be randomised after the operation into two groups.  
One will continue with the oestrogen pessaries and the other one will discontinue 
the treatment.  The investigator will still be blind to the second randomisation and 
will perform all the assessments.   
Patients will be followed up at 1, 3, 6 and 12 months post surgery.  A symptom 
questionnaire and a vaginal examination will be performed in each visit.  A QoL 
questionnaire will be completed at 6 and 12 months visits.  We can therefore look at 
the effect of oestrogen versus no treatment after 3 months treatment and the effect 
of oestrogen in preventing recurrent prolapse. Also repeated ultrasound scans will 
be performed for the patients in the study group at 6 months and 12 months post 
surgery to assess endometrial thickness. 
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Conclusions and Outlook: 
 
As only 49 women were recruited and of these only 28 had filled in both required 
questionnaires, no statistically significant data could be obtained considering Quality 
of life (QoL). Data for the 16 women that had biopsies taken were taken and 
calculated (See table below). 
 
Kings Health Questionnaire preliminary outcome: 
 
King’s Health questionnaire  pre Vagifem  post Vagifem 
General health perceptions score  33.6  25.0 
 Impact on life score  60.2  55.5 
 Role limitations score  44.3   46.5 
 Physical limitations score  53.2  49.4  
 Social limitations score  46.4  43.6   
 Personal relationships  score  46.3  44.6  
 Emotions score Sleep/energy score  37.9  34.4 
 Prolapse severity measures score  48.9  45.7 
 Urinary symptoms score  20.8  21.6 
 Frequency    1.7  1.5 
 Nocturia    0.2 0.3   
 Urgency    1.2  0.2 
 Urge incontinence  1.8  1.3 
 Stress incontinence   0.00   0.00   
Bulge/Lump    2.8   2.4 
Dragging    2.4  2.0 
Emptying of bowels  2.3  2.7 
Vaginal Discomfort  2.5  2.1 
Straining    1.3 1.3 
Urine dribbling    1.7 2.1 
Incomplete bowel emptying  2.2  2.3 
Constipation    2.6  2.1 
Straining BO    1.4 1.5 
Bulge in way of sex  2.3  2.1 
backache    1.3 1.6 
digitation    0.3  0.2 
BO frequency    2.6  2.5 
Table 1.1 Appendix, Mean for the QoL Assessment. The grey cells show an 
increase in the mean score and thus positive changes. Significance could not be 
established. 
 
 
The preliminary trend, after comparing the current data for the first three months of 
follow up, is promising though. It appears that Vagifem indeed is improving 
symptoms and QoL prior to surgery in a majority of cases, even though there are not 
sufficient data to determine significance. There is no trend to suggest a decreased 210 
 
recurrence rate as yet but certainly no deterioration of QoL was reported in the 
group using Vagifem for 18 months after surgery. 
Overall Vagifem was well accepted by the patients and no significant side effects 
could be detected. Endometrial thickness (EMT) was measured to assess oestrogen 
influence. Two women had an increase in thickness and one required a 
hysteroscopy for postmenopausal bleeding. In the first two cases, an increase of 
EMT of 2mm was noted, but hysteroscopy was not required. In the latter case, 
bleeding started 2 weeks after Vegifem therapy, but an urgently organised 
hysteroscopy demonstrated normal intrauterine cavity findings. No tissue could be 
obtained for histology and the bleeding settled down quickly.  
 
The continuation of the study would be extremely useful and interesting to not only 
demonstrate how vaginal oestrogens are changing the extracellular matrix of vaginal 
skin but also to examine if a regular use of this treatment should be established in 
clinical practice to support patients with their symptoms prior and after a prolapse 
surgery. 
 
 